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Abstract
Drug metabolism and transport are key areas in the drug development and therapy. The fate 
of a drug in the human body is determined by its physicochemical properties, which affect 
its absorption, distribution, metabolism and elimination processes within the body. The 
same processes also affect disposition of drug metabolites. Glucuronidation is the most 
important drug metabolism reaction besides oxidations. Glucuronidation of a drug produces 
glucuronic acid conjugates that are too hydrophilic to freely permeate cell membranes, and 
thus they require active transporters for their excretion. Knowledge of disposition of drug 
metabolites in humans is important for comprehensive understanding of the drug-related 
effects within the body. For example, glucuronide conjugates of some drugs inhibit drug-
metabolizing enzymes and transporters, which causes drug-drug interactions in humans. 
Therefore, investigations of the molecular mechanisms of drug metabolite excretion are 
needed.
Hepatic and intestinal ATP-dependent efflux transporters multidrug resistance-
associated protein 2 (MRP2, ABCC2), MRP3 (ABCC3), MRP4 (ABCC4) and breast cancer 
resistance protein (BCRP, ACBG2) have been identified to transport glucuronide 
metabolites of drugs in animal experiments and human in vitro assays. However, systematic 
studies that compare the properties of these human transporters and characterize their 
transport kinetics are often lacking. In this thesis, the transport activity of human MRP2-
MRP4 and BCRP was evaluated for 18 different glucuronide conjugates of drugs and drug-
like compounds, such as androgens and estrogens. The major findings were that MRP2 and 
MRP3 are rather non-selective transporters and accept most of the glucuronides investigated 
as their substrates. MRP4 and BCRP, on the other hand, exhibit rather selective transport 
and these transporters were active only toward some of the glucuronides that were tested in 
this thesis. P-glycoprotein (P-gp, ABCB1), another important drug efflux transporter, was 
also included in the assays. However, this transporter did not transport any of the 
glucuronides investigated. Transport kinetic analyses revealed low Km values for MRP3, 
mostly clearly below 100 μM. This indicates that MRP3 is a high affinity transporter for 
glucuronide metabolites in the liver and intestine, where it is highly expressed. The Km
values of MRP2 ranged from 120 to 800 μM. These values suggest that MRP2 is a low 
affinity, but possibly a high capacity, transporter in the same tissues as MRP3. MRP4 and 
BCRP exhibited Km values between 3-170 μM and 10-80 μM, respectively. In conclusion, 
MRP2, MRP3, MRP4 and BCRP are important efflux transporters that affect disposition of 
glucuronide metabolites of drugs in the human body. The affinity of glucuronides to these 
transporters may determine the different excretion of these drug metabolites in vivo, in 
either urine or bile.
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11 Introduction
Drug development of new small molecular entities requires numerous cycles of optimizations for 
various biological and molecular properties. Ultimately, efficacy and safety are the most important 
qualities of drugs, and only when they are acceptable a drug may enter the market and be available 
for patients. The disposition of a drug in the human body and its pharmacokinetics are among the 
key factors that control the extent of pharmacological effect of a drug and its off-target effects 
that might cause toxicity. For example, tissue accumulation of a drug or covalent binding of its 
reactive metabolites to cell proteins may cause toxic effects, which should be identified and 
circumvented during the optimization of drug metabolism and transport properties. The 
disposition and pharmacokinetic profile of a drug is the sum of various drug metabolism and 
transport processes that occur mainly in the liver but also in other tissues, such as in the intestine 
and kidney. Thus, the physicochemical and structural properties of a drug do not only determine 
its potency to a target and off-targets, but also control its permeability across membranes, affinity 
to a diverse set of different drug-metabolizing enzymes and transporters, and its subsequent 
elimination from the body (summarized in Figure 1).
Figure 1 Important properties of drugs and their relations. Efficacy and safety are the most important 
endpoints of drug development and they are affected by the exposure of a drug in the human 
body (pharmacokinetics) as well as its transfer to tissues and elimination from the body 
(disposition). The physicochemical properties of a drug determine its cellular effects such as 
permeability and affinity to drug-metabolizing enzymes and transporters, and to targets and 
off-targets.
The drug metabolism and transport processes can each be divided into classes of different 
functions, such as oxidation and conjugation reactions or uptake and efflux transport.
Furthermore, these reactions are often studied at the level of individual enzymes and transporters, 
and depending on the physicochemical properties of a drug and the location of its target in the 
human body, the right assays must be employed and developed. Although animal experiments are 
an inevitable part of drug development, the understanding of the precise function of individual 
human enzymes and cellular processes is required to build up comprehensive knowledge of drug 
action and its duration in humans. For example, emerging techniques such as physiologically 
based pharmacokinetic models require incorporation of parameters for the individual processes 
Pharmacokinetics
Disposition 
in the body
Metabolism and
Transport
Physicochemical 
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of a drug
Pharmacology 
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2that drugs undergo in tissues and cells. Another emerging area is precision medicine, for which 
the understanding of cellular processes of drugs is needed to translate the effects of genetic 
variations into clinical pharmacokinetics and disposition of drugs in humans. Lastly, knowledge 
of molecular processes and mechanisms of drug disposition in humans does not only significantly 
contribute to drug development but also to better understanding of disposition of endogenous 
compounds, such as steroids, and toxic byproducts of metabolism, such as bilirubin. Therefore, 
the findings of this thesis further apply to other small molecular xenobiotics and endogenous 
compounds, in addition to drugs. The scope of this thesis is to understand the effects of efflux 
transporters on the disposition of drug metabolites, more specifically glucuronide conjugates.
32 Background
2.1 Drug metabolism and transport
Drug metabolism has traditionally been divided into phase I and II reactions.1 This concept 
comprises functionalization and conjugation reactions, which are catalyzed by phase I and II 
enzymes, respectively. For example, cytochrome P450 (CYP) enzymes typically introduce a 
hydroxyl group into a drug and subsequently UDP-glucuronosyltransferases (UGTs) attach 
glucuronic acid to this hydroxyl (Figure 2). However, such classification is partially misleading, 
because conjugation reactions can be the primary metabolic route of a drug without prior phase I 
functionalization.1-3 Additionally, phase 0 and phase III concepts have been introduced to 
represent transport processes, together with phase I and II, as the whole concept of drug 
metabolism and transport (Figure 2).4 Phase 0 denotes the influx transport of a drug into tissues 
and it consists of passive permeability and carrier-mediated processes that is almost completely 
accounted for by solute carrier (SLC) transporters. Phase III denotes the active efflux transport of 
drug metabolites derived from phase II metabolism, which is mostly mediated by ATP-binding 
cassette (ABC) transporters. Currently, it is accepted that all the phases from 0 to III contribute to 
the clearance of drugs and affect their disposition in the human body, and that the sequential 
metabolism from phase I to phase II is not mandatory. Although these concepts help in 
understanding the different processes in drug metabolism and transport, a comprehensive 
understanding of all the mechanisms for a drug should be included and addressed as the whole, 
instead of as individual processes.5,6
Figure 2 The general concept of drug metabolism. Phase 0 transporters are part of the SLC family, 
whereas nearly all phase III transporters belong to the ABC family. A typical phase I 
hydroxylation reaction is catalyzed by CYP enzymes and it is often followed by conjugation, 
typically with glucuronic acid (Gluc), which is catalyzed by UGTs. Direct conjugation of a 
drug is also possible as indicated by the dashed line.
Drug metabolism reactions and transport processes are present in several tissues including the 
liver, intestine, kidney and blood.1,5 The liver is quantitatively the most important tissue in the 
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4clearance of drugs, which is a result of high expression of drug-metabolizing enzymes and 
transporters as well as the large size of the liver and high blood flow through it. The small intestine 
is important in restricting the absorption of orally administered drugs to the systemic circulation 
by different biotransformation reactions and efflux transport back to intestinal lumen.7 The
intestine might also facilitate the absorption of drugs via intestinal uptake transporters, such as the 
peptide transporter 1 (PEPT1).7,8 The kidney does not contribute to the first-pass effect of drug 
metabolism, however, it plays a significant role in the excretion of drugs from the human body to 
the urine.5 In addition, biotransformation reactions can occur in the kidney to some extent, which
indicates that the kidneys are not only excreting organs.1
The main goal of drug metabolism and transport optimization in drug development is the 
determination of a dose and dose interval for a drug.5 For a hepatically cleared and orally 
administered drug, Equation 1 presents the relation between the fraction absorbed (Fa) and the 
fraction escaping gut-wall extraction (Fg) as well as the hepatic intrinsic clearance (CLint,h), the
dose interval (τ) and dose. In addition, the pharmacological effect is related to the average plasma 
concentration (Css,av) that the drug should reach for its effect in the human body.
(1) ???? ? ? ???? ?? ??????? ?????? ???
Thus, the factors that affect Fa, Fg and CLint,h should be comprehensively known to describe 
the drug metabolism and transport processes of a drug. Fa is mostly determined by the dissolution 
and permeation properties of a drug, while Fg is dependent on the metabolic clearances in the 
intestine.6,9 CLint,h is the most important factor that affects the total clearance of a drug and it is 
described and discussed more comprehensively below (Figure 3, Equation 4).
Once a drug reaches the systemic circulation, the systemic clearance (CLsys) is defined not 
only by the hepatic clearance (CLh) but also by the clearances in other organs of which the kidneys 
and, accordingly, the renal clearance (CLr) are the most important (Equation 2, Figure 3).10
(2) ????? ? ???? ? ???
CLr is the factor of glomerular filtration rate (GFR) and the fraction of unbound drug in blood 
(fu) that is summed with the active renal secretion (CLsec) and subtracted by the fraction of drug 
that is actively and passively reabsorbed (Freabs).6 The metabolic clearance in the kidney should 
be included in CLr if the renal enzymes metabolize a drug. Furthermore, as CLsec is a transporter-
mediated process, the value of this term depends on the affinity of a drug to the renal transporters 
and subsequently it may have high impact on CLsys of some drugs. Equation 3 determines the total 
renal clearance of a drug.
(3) ??? ? ??? ? ??? ? ????? ? ????????? ? ??? ? ??????
Finally, the different phases of drug metabolism must be addressed as a whole, as discussed 
above, and thus the extended clearance model has been introduced for CLint,h, as described in 
Equation 4.6,10 CLint,h is determined by the active transporter-mediated hepatic influx and efflux 
clearances over the basolateral membranes of hepatocytes (CLinflux and CLefflux), the passive 
diffusion clearance (CLpassive), the metabolic clearance (CLmet) and the transporter-mediated efflux 
to bile (CLefflux,bile).
5(4) ??????? ?
?????????? ???????????? ???????? ?????????? ????
?????????? ??????????? ??????? ?????????? ????
Equation 4 defines the relations between metabolism and transport and their effect on the 
hepatic clearance of a drug (Figure 3). First, if a drug is not a substrate, or is a weak substrate, of 
uptake or efflux transporters and its passive permeability is high in comparison to the metabolic 
clearance, the metabolism determines alone the overall hepatic clearance (CLint,h≈CLmet). Second,
if a drug is a low permeable compound and a better substrate for uptake than efflux basolateral 
membrane transporters, then CLinflux will determine the clearance that will be independent of other 
processes (CLint,h ≈ CLinflux). Third, if the transporter and elimination clearances are in a similar 
range, it is important to include the contribution of all individual clearances in Equation 4 to the 
total hepatic intrinsic clearance of a drug. These three examples are simplified scenarios. 
However, they help understand the different disposition mechanisms and, in particular, they 
define the vital role of transporters alongside metabolism in the systemic clearance of drugs.
Figure 3 The main factors that affect the clearance of orally administered drugs. The red arrows are 
clearances that eliminate a drug, the green arrows are transporter-mediated processes that 
do not eliminate a drug but affect its systemic clearance and hepatic concentrations. The
blue arrow is independent of transporters.
2.1.1 Overview of drug metabolism reactions
Phase I oxidations are the most important drug metabolism reactions and they are mainly 
catalyzed by CYP enzymes.3,11 Up to 85% of the new molecular entities that were approved during 
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62006-2015 by the United States Food and Drug Administration (FDA) are metabolized via either 
phase I or II route.2 CYP-mediated oxidations are the primary metabolic route for 53% of the 
drugs, whereas of the phase II enzymes UGTs and hydrolases, such as esterases, contribute to the 
primary metabolism of 12% and 11% of the drugs, respectively. Although UGTs are not the 
primary clearance route for majority of the drugs, they may contribute to some extent to the
metabolism of up to 50% of drugs.12
The high impact of CYPs in drug metabolism is due to the various oxidation reactions that 
they catalyze.13 CYP-catalyzed reactions utilize molecular oxygen that is activated by heme-iron 
and the reduced nicotinamide adenine dinucleotide phosphate cofactor.13 The CYP enzyme 
reactions usually introduce aromatic or aliphatic hydroxyls into a drug molecule. Hydroxylation 
of an alkyl group adjacent to an oxygen or nitrogen atom leads to the cleavage of the alkyl chain, 
which results in O-dealkylation and N-dealkylation reactions, respectively. Hydroxylation and 
dealkylation reactions are the most important CYP-catalyzed reactions, since they functionalize a 
drug with a hydroxyl or an amine (Figure 4). These groups are prone to subsequent conjugation 
reactions that further lead to the excretion of the compound from the human body.1,4
Figure 4 Typical drug metabolism reactions that are catalyzed by the most important enzyme classes 
in drug metabolism.
Of the 57 CYPs, about a dozen are currently considered as the main enzymes in drug 
metabolism reactions.14,15 CYP3A4/5 enzymes are distinctly the most important CYPs, since they 
metabolize 84 of the 142 new drugs that were approved by the FDA during 2013-2017.16,17
CYP2D6, CYP2C19, CYP2C8 and CYP2C9 are the second most important individual enzymes 
in the metabolism of the same set of drugs. In particular, CYP2D6, CYP2C9 and CYP2C19 are 
important enzymes to consider in drug discovery, because these enzymes frequently have
polymorphic forms that may remarkably change pharmacokinetics of drugs.15 Additional CYPs 
that play a role in drug metabolism are CYP1A2, CYP2A6, CYP2B6 and CYP2E1.14,15
Esterases hydrolyze mostly carboxyl ester bonds in drugs but can also act on thioesters, amides 
and lactones.18,19 An esterase-catalyzed cleavage of a carboxyl ester bond in a drug molecule 
releases an alcohol or an amine and a carboxylic acid (Figure 4). Several different esterases are 
capable of metabolizing drugs but the most important and the best-characterized ones in drug 
metabolism are carboxylesterase 1 and 2 (CES1 and CES2), whereas others include arylacetamide 
deacetylase (AADAC), butyrylcholinesterase (BCHE) and paraoxonase 1 and 3 (PON1 and 
PON3). Moreover, esterases are important enzymes in the liberation of active moieties, such as 
alcohols, amines or carboxylic acids, of prodrugs.8 Different hydrolases activate 86% of prodrugs 
approved by the FDA during 2006-2015.2 Regardless of whether the hydrolysis leads to either 
Esterase-catalyzedCYP-catalyzed UGT-catalyzed
7active or inactive drug metabolite, the reaction produces chemical groups that are prone to 
subsequent conjugation reactions similar to the ones derived from CYP-catalyzed oxidations.19 A
distinct difference between esterases and other drug-metabolizing enzymes is that some esterases 
are secreted to the plasma from the liver and can exhibit high activity in blood.18,19
UGTs transfer a glucuronic acid from the uridine diphosphate glucuronic acid cofactor to a 
nucleophilic group in a drug, which results in a glucuronide conjugate of a drug.19,20
Glucuronidations of aliphatic and particularly aromatic hydroxyls, carboxylic acids and amines 
are the most prominent glucuronidation reactions (Figure 4). These chemical groups may be 
derived from CYP-catalyzed oxidations or esterase-catalyzed hydrolyses of a drug, as discussed 
above. However, many drugs contain within themselves aliphatic and aromatic hydroxyls or 
carboxylic acids that are readily available for glucuronidation. The UGT enzyme superfamily 
contains 22 different proteins of which subfamilies 1A and 2B are involved in drug metabolism. 
UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, 
UGT2B15 and UGT2B17 are currently known to be important in drug metabolism.19,21
Other important drug-metabolizing enzymes include, but are not limited to, aldehyde oxidase 
(AO), flavin-containing monooxygenases (FMOs), monoamine oxidases (MAOs), 
sulfotransferases (SULTs) and glutathione transferases (GSTs). CYPs, UGTs and esterases are 
the main metabolizing enzymes that contribute to the clearance of drugs, although AO, FMOs and 
MAOs play a role in specific cases and their contribution to drug metabolism might have been 
generally underestimated.1-3,11,14,22 FMO-catalyzed oxidations produce nitrogen and sulfur oxides, 
whereas AO produces mostly lactams and MAOs generate aldehydes, and thus these metabolites 
are not directly available for phase II conjugation reactions.22 SULTs, on the other hand, are phase 
II enzymes that contribute to the conjugation of similar compounds as UGTs, but mostly to a 
lesser extent.1,3 GSTs are classified as phase II enzymes and they transfer glutathione to 
electrophilic carbons, however, this reaction might also happen non-enzymatically in cells.4,23,24
In addition, glutathione conjugation can be a result of rather complex metabolic processes that
involve reactive and possibly toxic metabolites derived from CYP-catalyzed oxidations.24,25 These 
reactive metabolites are subsequently deactivated by GSTs or by spontaneous glutathione 
conjugation.
Human intestinal bacteria are also capable of catalyzing a high number of various 
biotransformation reactions.26 Of these reactions, deconjugations are the most prominent ones, 
particularly because numerous different bacterial β-glucuronidases catalyze the cleavage of 
glucuronic acid from glucuronide drug metabolites excreted to the intestine via bile.27,28 In such 
cases, the deconjugation hampers the elimination of a drug and this unconjugated drug can be 
reabsorbed from the intestine. The metabolic activity of bacteria may differ between the intestinal 
segments, and, for example, β-glucuronidase activity increases highly toward the colon.28
Nevertheless, orally administered drugs are exposed to the intestinal bacteria and thus the 
contribution of bacteria to the metabolism of drugs should not be overlooked.
2.1.2 Drug metabolism in the intestine, liver and kidney
Most drugs are administered orally, which means that a drug must pass the intestinal epithelium 
before it reaches the portal vein and subsequently the liver. However, the intestinal barrier restricts 
the absorption of drugs and other exogenous compounds in humans not only physically but also 
by expressing several drug-metabolizing enzymes in enterocytes. The first-pass clearance of a 
drug must be assessed as two separate clearance processes, one in the intestine and the other one 
8in the liver.5 These two factors, Fg and the fraction escaping hepatic extraction (Fh), can differ 
markedly for the same drug, which emphasizes the contribution of different enzymes in both the 
liver and intestine.9,29 This difference is particularly true for UGTs whose enzyme expression 
patterns vary substantially between the liver and intestine (Table 1), which might contribute to the 
low Fg of drugs that are substrates for UGTs, as discussed below.30,31
Table 1. The main drug-metabolizing enzymes in the intestine, liver and kidney. See the text for 
details and references.
Enzyme Intestine Liver Kidney 
CYP CYP3A4 
CYP2C9 
CYP3A4 
CYP2C9 
CYP1A2, CYP2A6, CYP2C8 
CYP2B6, CYP2D6, CYP2C19  
CYP3A5 
 
CYP2B6  
CYP3A5 
UGT UGT2B17 
UGT1A1  
UGT1A10 
UGT2B7 
UGT1A1, UGT2B7 
UGT1A4, UGT1A9, UGT2B4, UGT2B10, UGT2B15 
UGT2B17, UGT1A3, UGT1A6 
 
UGT1A9 
UGT2B7 
UGT1A6 
 
Esterase CES2 
AADAC 
CES1 
AADAC 
PON1, PON3, BCHE 
CES2 
CES2 
The intestine expresses drug-metabolizing enzymes along its whole length from duodenum to 
rectum, although the absolute amounts and expression pattern of the enzymes vary with different 
segments, and the most enzymes are expressed only in the small intestine.32-36 Drug absorption 
occurs mainly in the small intestine and especially in its proximal parts, which also have the 
highest expression of the drug-metabolizing enzymes.34,37
CYP3A4 is quantitatively the most abundant CYP enzyme in the human small intestine and it 
constitutes over 80% of the drug-metabolizing CYPs in this tissue.34,38,39 The second most 
abundant CYP enzyme in the small intestine is CYP2C9, which represents 10-20% of the drug-
metabolizing CYPs, whereas CYP2C19, CYP2D6 and CYP3A5 constitute a few percent of the 
intestinal CYP enzymes. The absolute protein concentration of CYP3A4 in the small intestine is
equal to the liver. This similarity is also reflected by the activity of CYP3A4 that is similar in 
microsomal preparations from the human small intestine and liver.40 On the other hand, the 
activities of CYP2C9, CYP2C19 and CYP2D6 are present in intestinal microsomes but only to 
some extent.41 Fg value for drugs that are substrates for CYP3A4/5 can be as low as 0.1, whereas 
Fg > 0.75 is observed for drugs that are metabolized by CYP2C9, CYP2C19 and CYP2D6, which 
emphasizes the major contribution of CYP3A4 to drug metabolism in the human small 
intestine.42,43
The drug-metabolizing UGTs are expressed either in both the liver and extrahepatic tissues or 
only extrahepatically.19,20 The most prominent feature among UGTs is UGT1A10, which is not 
expressed in the liver but it exhibits high expression along the intestine.30-32,44 Other UGTs 
expressed in the intestine are UGT1A1, UGT2B7 and particularly UGT2B17 that has the highest 
expression level of the intestinal UGTs in humans. Nakamori and coworkers demonstrated an 
inverse correlation between the clearance in human intestinal microsomes and Fa x Fg for 11 drugs 
that are substrates for human UGTs.45 The lowest calculated Fa x Fg values were for raloxifene 
(0.05) and quercetin (0.002), and these values were much lower than has been reported for drugs 
9that are substrates of CYP enzymes.42,45 More importantly, Cubitt and coworkers demonstrated 
six- and nine-fold higher scaled clearance values for raloxifene and troglitatzone in the human 
intestine than liver.46 The intestine-specific UGT1A10 catalyzes the glucuronidation of raloxifene
and troglitatzone, which explains the high clearance of both drugs in the small intestine and the 
low Fa x Fg value for raloxifene.47,48 On the other hand, the activity of UGT1A10 only partly 
explains the high intestinal glucuronidation of quercetin but the activity of UGT1A1 might play 
a higher role in this case.45 The activity of UGT2B7 in the intestine has been demonstrated to 
restrict oral bioavailability of morphine but to a much lesser extent than drugs that are highly 
glucuronidated by UGT1A10.49,50 The high expression of UGT2B17 in the human intestine 
contributes to the low bioavailability of testosterone.36,51 Together, four UGTs highly catalyze 
glucuronidation of drugs in the small intestine and restrict their absorption, while of the CYPs 
only CYP3A4 is highly expressed and active in the intestine.
The most important human intestinal esterase is CES2 that is also expressed in the liver, 
whereas CES1 is absent from the intestine.52 In the liver, on the other hand, the expression of 
CES1 is about 20- to 30-fold higher than the expression of CES2.53 AADAC is expressed similarly 
in both tissues, while PON1, PON3 and BCHE are expressed highly only in the liver but are also 
secreted to the plasma, and together they contribute to the inactivation of several drugs.18,19,54
Although the substrate preferences of CES1 and CES2 overlap, the absolute hydrolysis rates can 
differ between these two enzymes. For example, CES2 hydrolyses the prodrug prasugel in the 
intestine to a metabolite that is further converted by CYP3A4 to an active metabolite.55 In
addition, CES1 hydrolyses prasugel in the liver, while AADAC contributes to approximately half 
of the hydrolysis in both the intestine and liver, indicating overlapping substrate specificity 
between all three of these esterases.19,55 Clopidogrel, on the other hand, is hydrolyzed in the liver 
only by CES1 to an inactive metabolite and this hydrolysis reaction is undetectable in intestinal
microsomes.56 Furthermore, the human plasma PON1 hydrolyses 2-oxo-clopidogrel, a CYP3A4-
derived metabolite of clopidogrel, to an active thiol metabolite, while CES1 inactivates these two 
metabolites of clopidogrel, as well as the parent drug itself.57 Together, the aforementioned 
esterases have a high impact on drug metabolism in the intestine, liver and plasma.
In the liver, CYP3A4 is also the most prominent drug-metabolizing enzyme, but this tissue 
expresses several other CYPs that are absent from the small intestine.34,58 CYP2C9 is the second 
most highly expressed enzyme in the liver, and its expression is almost the same as the expression
of CYP3A4. The expression of CYP1A2 is half in comparison to CYP3A4, while CYP2A6, 
CYP2B6, CYP2C8, CYP2C19, CYP2A6 and CYP3A5 are expressed at levels of 10 to 30% of 
the expression of CYP3A4. Although the average hepatic protein expression of CYP3A5 is lower 
than for CYP3A4, its role in drug metabolism might be much greater, because the CYP3A5 gene 
is highly polymorphic leading to great variation in its protein expression.34,58,59 In addition, 
CYP3A4 and CYP3A5 are highly homologous enzymes, exhibiting similar clearances for the 
same compounds.59 In fact, CYP3A5 might have an even higher or similar contribution as 
CYP3A4 to the clearance of some drugs in individuals who express a high amount of CYP3A5 
protein in their livers.
The liver expresses several UGTs, including some that are absent from the intestine.30,31
UGT1A1 and UGT2B7 are the main UGTs in the human liver. Other highly expressed hepatic 
UGTs are UGT1A4, UGT1A9, UGT2B4, UGT2B15, while the expression of UGT1A3, 
UGT1A6, UGT2B10 and UGT2B17 is a few-fold lower. UGT1A4 and UGT2B10 are particularly 
significant hepatic enzymes, since they catalyze glucuronidation of amines, whereas the other 
UGTs are rarely able to catalyze that activity.19,60 Thus, these two UGTs have an essential role in 
the clearance of amine containing drugs. UGT1A1 is another highly important UGT, because it 
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solely catalyzes the detoxification of the endogenous heme metabolite bilirubin.19,20 Other hepatic 
UGTs usually overlap in their substrate preferences, and thus all these enzymes are involved in 
drug metabolism reactions to some extent.19,21
The UGTs expressed in the human kidney are UGT1A6, UGT1A9 and UGT2B7.30,31 The
expression levels of UGT1A6 and UGT2B7 are lower in the kidney than in the liver, whereas 
UGT1A9 is expressed at a three-fold higher level in the kidney than in the liver. Although the 
kidney does not contribute to the bioavailability of drugs, it might affect the total systemic 
clearance of some drugs, as discussed above in Section 2.1. However, blood flow through kidneys 
and the tissue size are smaller than the respective values for the liver.61 Gill and coworkers 
measured higher clearance for the UGT1A9 substrates mycophenolic acid and propofol in 
microsomes from the kidney than liver, while for UGT2B7 substrates the clearance was similar 
in both preparations.61 The renal UGT1A9 appears to contribute significantly to the systemic
metabolism of propofol, because the metabolic renal clearance of this drug in the human kidneys 
is almost equal to its hepatic clearance.62
CYP2B6 and CYP3A5 are expressed in the human kidneys, while the expression of CYP3A4 
is undetectable or low.38,63,64 Interestingly, in addition to glucuronidation, propofol is metabolized 
by CYP2B6, which might contribute to the renal metabolism of this drug.65 Low expression of 
CYPs implicates that the kidney has a low contribution to CYP-catalyzed drug metabolism and 
drug-drug interactions, whereas renal glucuronidation clearly has an impact on the systemic 
clearance of some drugs, and should be considered in specific cases.61,64 CES2 is expressed in the 
human kidney while CES1 is absent, which is similar to the expression pattern of these esterases 
in the small intestine.52 In addition, AADAC is not expressed in the kidney.54 No other esterases 
involved in drug metabolism are expressed in the kidney or are currently identified in this 
tissue.18,19
2.1.3 Overview of drug transporters
The two types of transporters involved in drug disposition are uptake and efflux transporters. 
Uptake transporters concentrate their substrates from the extracellular space into the cells, 
whereas efflux transporters carry their substrates from the inside of the cells to the extracellular 
space over the membrane (Figure 2). Uptake transporters belong to the SLC family, whereas most 
of the efflux transporters are part of the ABC family, members of which utilize energy from ATP 
hydrolysis to drive their transport.66,67 Contrary to ABC transporters, SLC transporters do not 
hydrolyze ATP but, depending on the transporter, might exchange or cotransport their substrates 
with sodium ions, protons or other ionic species.66,68 Together the ABC and SLC superfamilies 
contain several hundred different transporters of which only a small subset is currently known to 
be important in drug disposition.7,66,67,69 Drug transporters are expressed in the same tissues as 
drug-metabolizing enzymes, namely in the liver, intestine and kidney (Table 2).7 In contrast to
drug-metabolizing enzymes, drug transporters play a pivotal role in the blood-brain barrier (BBB) 
by restricting the access of drugs to the brain, and thus transporters significantly affect drug 
disposition and efficacy also in the human central nervous system.7,70 In addition, efflux 
transporters protect many tissues from drugs, such as at the placenta by restricting the access of 
drugs and other foreign compounds to the fetus.71
Currently, the most important uptake transporters in drug disposition are organic anion 
transporting polypetides 1B1, 1B3 and 2B1 (OATP1B1, OATP1B3, OATP2B1) and organic 
anion transporters 1-3 (OAT1, OAT2, OAT3), which are involved in the hepatic and renal uptake 
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transport of anionic and zwitterionic drugs and their metabolites.7,69,72,73 Furthermore, organic 
cation transporters 1 and 2 (OCT1 and OCT2) are important for the uptake of cationic drugs into 
the liver and kidney, respectively.7,69,73 Lastly, other uptake transporters of emerging interest 
include OAT7, OATP4C1, PEPT1, the sodium/taurocholate co-transporting polypeptide, 
heteromeric organic solute transporter and the equilibrative nucleoside transporters 1 and 
2.7,8,69,73,74
Table 2. The main drug transporters in the intestine, liver and kidney. The gene names are 
indicated in brackets. See the text for details and references.
Intestine Liver Kidney 
Uptake transporters PEPT1 (SLC15A1) OATP1B1 (SLCO1B1) 
OATP1B3 (SLCO1B3) 
OATP2B1 (SLCO2B1) 
OAT2 (SLC22A7) 
OCT1 (SLC22A1) 
 
OAT1 (SLC22A6) 
OAT3 (SLC22A8) 
OCT2 (SLC22A2) 
Efflux transporters P-gp (ABCB1) 
BCRP (ABCG2) 
MRP2 (ABCC2) 
MRP3 (ABCC3) 
MRP4 (ABCC4) 
P-gp (ABCB1) 
BCRP (ABCG2) 
MRP2 (ABCC2) 
MRP3 (ABCC3) 
MRP4 (ABCC4) 
MATE1 (SLC47A1) 
MATE1 (SLC47A1) 
P-gp (ABCB1) 
MRP2 (ABCC2) 
MRP4 (ABCC4) 
 
Breast cancer resistance protein (BCRP) and P-glycoprotein (P-gp, MDR1) are unequivocally
the most important efflux transporters that affect the drug disposition and absorption in several 
different tissues, including the intestine, liver and kidney.7,69 The clinical significance of other 
efflux transporters has not been proven as comprehensively as for the uptake transporters. Thus, 
besides BCRP and P-gp, only multidrug and toxin extrusion transporters 1 and 2K (MATE1 and 
MATE2K) are currently known to be involved in drug-drug interactions or have polymorphic 
variations that affect the pharmacokinetics and efficacy of drugs.69 Multidrug resistance-
associated proteins 2, 3 and 4 (MRP2, MRP3 and MRP4) still lack robust clinical evidence of 
their contribution to drug-drug interactions or polymorphic variations in the pharmacokinetics of 
drugs.7,69 However, overall evidence suggests that they are the main carriers for anionic drugs and 
drug metabolites in the intestine, liver and kidney and, therefore, are clinically highly relevant 
transporters.7,69,73,75
Identification of the contribution of specific transporters to drug disposition is challenging, 
because the tissue uptake and efflux of a drug is not always quantifiable in vivo in humans and 
does not result in the biotransformation of a drug, such as in the case of drug metabolism 
reactions.7,75,76 In addition, deriving influx and efflux parameters from the net transport into the 
tissue, such as in the liver, might be impossible. Hence, it is obvious that the landscape of drug 
transporters is not yet established as completely as for drug-metabolizing enzymes, and the 
knowledge of transporters will expand in the future.
2.1.4 Drug transporters in different tissues
The small intestine exhibits high expression levels of efflux transporters in enterocytes, both in 
the apical membranes facing the intestinal lumen and in the basolateral membranes at the blood 
circulation side (Figure 5). BCRP and P-gp are localized to the apical side and exhibit increasing 
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expression levels toward the ileum, while their levels in the colon are lowest along the 
intestine.7,77,78 MRP2 and MRP3 are efflux carriers in the intestine with higher expression levels 
than BCRP and P-gp, particularly in the colon where they are the two main transporters. MRP2 is 
localized to the luminal side of enterocytes, while MRP3 is localized to the basolateral 
membranes. MRP4 is another intestinal transporter from the MRP family, which is expressed at 
similar levels as MRP3 along the whole intestine, but the localization of MRP4 has not been 
confirmed yet in human intestinal tissues.77 MRP4 is localized to the apical membranes of cells 
of the human epithelial colorectal adenocarcinoma cell line, Caco-2.79 Additional evidence for the 
basolateral localization of MRP4 in enterocytes comes from a knockout mouse study.80 That study 
found lower basolateral transport of the MRP4 substrate cephadroxil across isolated jejunal tissue 
from mice lacking Mrp4 compared to the tissue from wild type mice.
The small intestine expresses a few uptake transporters in the apical membranes of enterocytes 
and these transporters might facilitate the drug absorption.7,69,73 PEPT1 is essential for the 
absorption of small peptides but it also carries drugs, and thus it plays a role in the absorption of 
peptide-like drugs or prodrugs designed to be carried by this transporter.8,69,78 OATP-mediated 
absorption of some hydrophilic drugs has been postulated and OATP2B1, a rather highly 
expressed transporter in the intestine, might be responsible for these observations.77,78,81,82
However, the localization of OATP2B1 in enterocytes is under debate and future studies are 
warranted to clarify whether this transporter affects drug disposition, drug absorption or both in 
enterocytes.73,82
Figure 5 Localization of the main drug transporters in hepatocytes, enterocytes and proximal tubule 
cells. In addition to the indicated transporters, multiple other drug carriers are expressed in 
these tissues. See text for details and references.
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The liver expresses almost the same main efflux transporters as the intestine, but their relative 
expression levels are different.77,83 The expression of BCRP is low in the liver, whereas the 
abundance of P-gp is clearly higher but its amount is only half of its intestinal amount. The 
expression of MRP2 is higher in the liver than along the intestine, whereas the expression of 
MRP3 is similar to the intestine, and MRP4 is almost undetectable in the liver. Localization of 
the aforementioned transporters is similar in hepatocytes as in enterocytes that is BCRP, P-gp and 
MRP2 are found in the apical membranes at the bile side, while MRP3 is localized to the 
basolateral membranes at the blood side (Figure 5).7 Furthermore, MRP4 is localized to the 
basolateral membranes of hepatocytes.
The liver also expresses several other efflux transporters, which are presumably associated 
with drug disposition or toxicities. The highly expressed apical membrane transporters are bile-
salt export pump and multidrug resistance protein 3, which are vital to maintain bile homeostasis 
by transporting bile acids and phosphatidylcholine, respectively.7,69,73,77,83 These transporters are 
not known to affect drug disposition, but their inhibition by drugs or drug metabolites might lead 
to impaired formation of bile and potentially to drug-induced liver injury.69,73,84 MATE1 is a 
canalicular transporter in hepatocytes and it exhibits similar protein expression as MRP2 and P-
gp.69,77,83 Although MATE1 affects disposition of some drugs in the liver, this transporter might 
play a more prominent role the in the renal secretion than biliary excretion of drugs. Other MRPs 
localized to the basolateral membranes of hepatocytes are MRP1, MRP5 and MRP6.85 Some 
studies have reported similar protein expression of these transporters as MRP2 and MRP3, 
although the roles of MRP1, MRP5 and MRP6 in drug disposition are not well-established.83,85
Several uptake transporters are highly expressed in the liver and affect disposition of many 
drugs.7,68,69 OATP1B1 and OATP1B3 are highly expressed in the basolateral membranes of 
hepatocytes and are the most comprehensively studied transporters, which carry drugs into 
hepatocytes from the systemic circulation (Figure 5).68,77,83 OATP2B1, OAT2, and OCT1 are 
expressed only at a few-fold lower protein levels than OATP1B1 and OATP1B3 in the same 
membrane.77,83 The protein expression of these uptake transporters is higher in comparison to the 
hepatic efflux transporters MRP2-4, BCRP and P-gp.
In the kidney, the transporters are expressed both in the apical and basolateral membranes of 
proximal tubule cells where they may contribute to the active renal secretion or reabsorption of 
drugs.7,69 MRP4 is localized to the apical membranes of proximal tubule cells alongside MRP2, 
P-gp and MATE1, and these proteins contribute to the active secretion of their substrates in urine. 
The protein expression levels of MRP2, MRP4 and P-gp are similar, whereas the expression of 
MATE1 is a few-fold higher.86-88 OAT1, OAT3 and OCT2 are the most highly expressed renal
uptake transporters in the basolateral membranes of proximal tubule cells and they contribute to 
the active excretion of drugs.7,86,88 While OAT2 is also localized to the basolateral membranes of 
these cells, its expression level is several-fold lower than the levels of OAT1 and OAT3, and thus 
its effect on the active renal secretion of drugs is not yet established.73,86,88 The renal expression 
of BCRP, MRP3 and MATE-2K is low or undetectable.86-88 Therefore, their role in the renal 
secretion of drugs may be negligible.
The BBB is perhaps the most important tissue for drug disposition apart from the liver, 
intestine and kidney. Although several transporters are expressed in the epithelial cells of the 
BBB, BCRP and P-gp are the most important efflux transporters restricting the brain availability 
of drugs.7,70,89 Evidence from numerous reports has implied that BCRP and P-gp play a synergistic 
role in restricting the distribution of drugs into the brain from the systemic circulation.70 The
efficacy of these two transporters almost completely abolishes access of multiple drugs into brain.
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2.2 Excretion of drugs and disposition of their metabolites
A drug is cleared from the body by direct excretion in urine or bile, or after conversion to 
metabolites by drug metabolism reactions.5 However, the excretion of a drug is complete only 
after all drug-related material including metabolites exit via urine or feces from the human body. 
Drug metabolites may possess similar, or even higher, pharmacological activities compared to the 
parent drug or be the cause for toxic effects of drugs.90 Therefore, understanding the disposition 
of drug metabolites, not only of the parent drug, is an inevitable part of the development of new 
drugs.90,91
2.2.1 Effects of transporters and physicochemical properties on the excretion
routes
The main excretion routes for drugs and drug metabolites are via urine or feces.5 Urinary excretion 
is driven by glomerular filtration of an unbound compound in blood and by the net effect of active 
secretion and reabsorption as well as passive reabsorption in the kidney (Equation 3). Biliary 
excretion is the first step in the excretion of drugs in feces, although in some specific cases 
enterocytes can directly eliminate drugs from the systemic circulation, which can result in a 
phenomenon called enteroenteric circulation.92,93 Examples of enteroenteric circulation in humans 
are rare, albeit this excretion route might be important for some drugs; for example, the intestinal 
secretion contributes to one-third of the total excretion of urate, an endogenous compound, in 
mice.94 On the other hand, biliary excretion of unchanged drugs is rather common.28 In most cases, 
it leads to enterohepatic circulation of drugs and this drastically prolongs their half-life. A 
representative example of a drug that undergoes enterohepatic circulation is atovaquone.95 This
drug exhibits negligible metabolism and excretion in urine but has high biliary excretion, which 
prolongs its half-life to several days in humans. Such a long half-life indicates that the drug is 
extensively reabsorbed from the small intestine and only slowly excreted in feces. Hence, biliary 
excretion should be considered as a distribution rather than an excretion mechanism, even in the 
case of some drug metabolites such as glucuronides, which may be efficiently deconjugated in the 
intestine, leading to reabsorption of the parent drug.27,28
It is well established that physicochemical properties determine the extent of metabolism and 
transport of drugs and their metabolites.5,6,9,96,97 Nevertheless, predicting the fate of an individual 
drug is challenging even though some general correlations exist between molecular properties and 
in vivo outcome. Drugs and drug metabolites excreted in urine are hydrophilic and often carry a 
charge, because lipophilicity increases passive reabsorption in the kidney and prevents the 
excretion of drugs in urine.5,98 In addition, CLr is decreased proportionally with fu, whereas 
lipophilicity further decreases the fu value.5,96 Similarly, biliary excretion is also limited for drugs 
that possess high passive permeability.92,99 Highly lipophilic drugs distribute back to blood from 
the hepatocytes and therefore are less prone to be excreted and concentrated in bile. Furthermore, 
a drug must permeate the hepatic basolateral membrane before excretion in bile, and thus the 
uptake into the liver can be the rate-liming step prior to efflux transporter-mediated biliary 
excretion of the drug.10
In addition to lipophilicity, the MW and ionization state of a drug affect its biliary 
excretion.28,92,100 In rats, anionic drugs are more prone to biliary excretion than cationic, 
zwitterionic or neutral species.99 Furthermore, a MW threshold of about 400 Da for biliary 
excreted anions has been determined in rats, whereas the corresponding value for humans was 
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reported to be about 500 Da.99-101 Interestingly, the physicochemical property space of biliary 
excreted drugs overlaps with the substrates of rat Oatp1b2 and three human hepatic OATPs, and 
these drugs are mostly anions with a mean MW of about 500 Da.99 In addition to the MW and 
negative charge, higher polar surface area (PSA) of drugs correlates with the extent of biliary 
excretion in rats but also with the substrates of human hepatic OATPs, which have a mean PSA 
value of 126 Å2.99,102 These observations strongly indicate that the hepatic basolateral organic 
anion uptake transporters, together with the organic anion efflux transporters in the canalicular 
membranes, play a key role in the biliary excretion of anionic drugs and drug metabolites. Thus, 
the excretion in urine and bile are the main elimination routes for low permeable compounds, 
whereas lipophilic drugs have to undergo metabolism before excretion as drug metabolites with 
reduced lipophilicity.5
Several different classification systems are available for the prediction of disposition 
mechanisms of drugs based on their physicochemical properties, the rate of metabolism and 
permeability.103 The extended clearance classification system (ECCS) classifies drugs into four 
main classes: high permeable acids and zwitterions (Class 1), high permeable bases and neutral 
drugs (Class 2), low permeable acids and zwitterions (Class 3), low permeable bases and neutral 
drugs (Class 4).6 Acids and zwitterions are further separated by MW with a cut-off value of 400 
Da. Thus, acidic and zwitterionic drugs below 400 Da are classified in Class 1A and 3A, whereas 
larger compounds are in Class 1B and 3B.
The ECCS improves the understanding of the effect of physicochemical properties on the 
clearance mechanisms of drugs and the role of transporters. Class 1A and 2 compounds are mostly 
cleared by metabolic reactions, whereas renal clearance is observed only for low permeable drugs 
in Class 3 and 4. Hepatic uptake transporters mostly affect the disposition of compounds in Class 
1B and 3B, whereas renal transporters might affect the clearance of compounds in Class 3 and 4. 
It should be noted that although the hepatic uptake would be the clearance mechanism for most 
of Class 1B drugs, these drugs are anticipated to be highly metabolized in the liver and the uptake 
transport is only the rate-liming step for the clearance. Effects of efflux transporters on drugs in 
different ECCS classes are less robustly determined, although their contribution would be most 
important for the low permeable compounds in Class 3 and 4.104 The intestinal absorption process 
is predicted to be complete (Fa~1) for drugs in Class 1 and 2, whereas drugs in Class 3 and 4 may 
have lower intestinal absorption that is further decreased by efflux transporters.
The basis for the MW cut-off value in ECCS classes 1A and 3A is the preference of OATPs 
to transport higher MW anions, as discussed above.99 This preference correlates with the MW 
threshold, 400-500 Da, of the majority of biliary excreted anionic compounds in humans and 
rats.28,99-102 On the other hand, renal excretion is negligible for highly passive permeable 
compounds, as discussed above, and therefore only compounds in ECCS Class 3 and 4 are mainly 
excreted as such in urine.5,98,99 Because of the complex relationship between the uptake transport, 
efflux transport and metabolism, the prediction of biliary excretion is challenging. Therefore, the 
biliary excretion of the parent drug is presumably the predominant clearance route only for Class 
3B compounds, which are substrates for hepatic OATPs but do not undergo metabolism. 
Nevertheless, biliary excretion of other low passive permeable drugs in Class 3A and 4 may also 
be possible.
Recently, the hepatic OAT2 was identified to transport several ECCS Class 1A drugs, which 
are not carried by OATP1B1.72 Furthermore, the renal OAT1 and OAT3 carry several drugs from 
Class 3A and 4, and some drugs from Class 1A.105 Thus, the total systemic clearance of drugs is 
a complex effect of different transporters, including OATs and OATPs, which affect the hepatic 
and renal clearance. The current understanding of intrinsic molecular properties of drugs that 
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affect the elimination route and effects of transporters on the elimination of drugs are summarized 
in Table 3.
Table 3. The main elimination routes for drugs, the transporter effects and the intrinsic molecular 
properties of drugs that affect their elimination. ECCS classification is 
indicated.5,6,72,98,100,101,104,105
Main elimination 
route 
Effect of the intrinsic molecular properties and transporters,  
and ECCS classification 
Metabolism logD > 0, PSA < 75 Å2, high permeability, Fa~1 
ECCS 1A, 1B and 2 
Transporters: Hepatic OAT2 (ECCS 1A) and OATPs (ECCS 1B) as the rate-limiting step in 
the elimination 
 
Biliary MW > 400-500 Da, PSA > 75 Å2, a negative charge,  
low to medium permeability and LogD 
ECCS 3B 
Transporters: Hepatic OATPs, intestinal and hepatic efflux transporters (P-gp, BCRP, MRP2) 
 
Renal logD < 0, PSA > 75 Å2, high fu, low permeability 
ECCS 3A, 3B and 4 
Transporters: Renal OAT1, OAT3 and OCT2, intestinal efflux transporters 
2.2.2 Disposition of drug metabolites
Prediction of the systemic exposure is important for the evaluation of safety and activity of drug 
metabolites.106 The systemic exposure also affects the renal clearance of a drug metabolite, since 
only the unbound compound in blood can be excreted in urine.5 Thus, it is important to understand 
the mechanisms that determine the excretion routes and the extent of systemic exposure of drug 
metabolites, not only the parent drug. Most of the pharmacologically active metabolites are
derived from oxidative and reductive metabolic reactions that result in minor modifications to a 
drug, such as hydroxylation. In addition, hydrolysis of prodrugs usually releases an active 
carboxylic acid metabolite.3,8,90 Apart from prodrugs, conjugation or hydrolysis reactions do not 
typically produce active or toxic metabolites, although several examples are found among them 
that are active or toxic.3,90 For example, the glucuronide conjugates of the cholesterol absorption 
inhibitors S-8921 and ezetimibe are 6000- and several-fold more potent inhibitors than their parent 
drugs, respectively.107,108 In addition, some glucuronide conjugates mediate drug-drug 
interactions. For example, clopidogrel and gemfibrozil glucuronides inhibit both CYP2C8 and 
OATP1B1.109 Furthermore, glucuronide metabolites of several nonsteroidal anti-inflammatory 
drugs were found to inhibit the renal uptake and efflux transporters OAT1, OAT3, MRP2 and 
MRP4, although the clinical significance of the inhibition is not yet known.110 Hence, more 
interest has recently been raised in glucuronide metabolites.
Oxidative metabolic reactions, such as hydroxylation or dealkylation, generally result in a 
reduction of no more than a couple of logP units in lipophilicity of the metabolite compared to the 
parent drug.111-113 Such a small decrease means that the metabolites derived from oxidation 
reactions usually retain similar permeation properties as the parent drug, if the drug itself is highly 
permeable. In the aforementioned cases, the systemic exposure of metabolites will be determined 
by the fraction metabolized via this specific route.111,114 If the specific metabolic route is 
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dominant, the exposure of the metabolite is often high. However, some metabolites might exhibit 
negligible systemic exposure even though the major clearance of the drug is via this specific route 
and the formed metabolite is also found in human excreta.111,115 In particular, multistep metabolic 
reactions, such as aromatic oxidation, which results in a phenol that is subsequently conjugated 
with glucuronic acid or sulfate, leads to a high systemic exposure of the conjugate but to low 
systemic exposure of the first formed metabolite. In vitro the opposite might be true. More 
discrepancies between the fraction metabolized value and the systemic exposure are observed for 
hydrophilic metabolites, whose disposition is restricted by membrane-permeability and depends 
on active transporters.111,113,115 For example, conjugated metabolites and particularly glucuronides 
might reach high systemic exposures.113 In some cases, glucuronides may have drastically 
different disposition in humans than what is anticipated based on the in vitro fraction metabolized 
by glucuronidation of the parent drug. For instance, glucuronidation is the only metabolic route 
for cabotegravir and pradigastat in vitro, but their glucuronide conjugates were not found in the 
systemic circulation in humans.116,117 Pradigastat is completely excreted in feces, whereas 
cabotegravir is partly excreted in urine as cabotegravir-glucuronide but most of the dose is 
excreted as the parent drug in feces. In both cases, the glucuronide metabolite is most likely 
excreted via bile to the intestine and then deconjugated by bacterial β-glucuronidase that releases
the parent drug.
Glucuronidation, the most important conjugation reaction, results in a reduction of 
lipophilicity of a drug by several logP units and adds a negative charge to it.113,118 Furthermore,
glucuronidation increases the MW of a drug by 176 Da, which mostly leads to metabolites with 
MWs above 400 Da since the MW of a typical drug is 200-600 Da.96 Glucuronide metabolites 
demonstrate over an order of magnitude, typically 50-fold, decrease in the permeability compared 
to their parent drugs.119-124 Such a decrease in the permeability is distinct in comparison to 
metabolites originating from oxidative metabolism. Therefore, the human exposure of 
glucuronide metabolites is not fully predictable only based on the knowledge of the extent of 
glucuronidation. This is because the membrane-barrier restricts the diffusion of glucuronides, and 
thus the permeation is affected by the efficiency of different transporters rather than by the 
physicochemical properties of the metabolite alone.113,125
Carboxylic acid metabolites, derived from oxidation or hydrolysis reactions, might exhibit 
permeability-limited systemic exposure and therefore transporters may affect their systemic 
disposition and excretion in either bile or urine.111 For example, losartan is metabolized to a 
carboxylic acid metabolite, which has a 20-fold lower passive permeability but only 2-fold lower 
total influx, including passive and active, than the parent drug in human hepatocytes.126
Furthermore, the carboxylic acid metabolite of losartan has a 50-fold higher basolateral efflux
than losartan, which agrees with several times higher systemic concentration of the metabolite in 
comparison to the parent drug in humans. Such an example elegantly emphasizes the importance 
of active basolateral carriers in determining the systemic exposure of carboxylic acid metabolites. 
Similarly, membrane-limited permeability controls the disposition of the dicarboxylic acid 
metabolite enalaprilat, which is formed from the monocarboxylic acid parent drug enalapril.127
Enalaprilat reaches seven-fold higher systemic exposure than enalapril in humans. In addition, 
60% of the total excreted enalaprilat is found in urine and the rest in feces, which indicates that 
both apical and basolateral transporters are similarly active in the human liver. In perfused rat 
livers, the basolateral efflux of enalaprilat is slightly higher than the apical efflux, which agrees 
well with almost the equal excretion of enalaprilat to urine and feces via bile.128 Moreover, the 
hepatic influx of enalaprilat is 20-fold lower than its efflux clearances. The examples of losartan 
and enalapril clearly demonstrate that their hydrolysis results in metabolites with markedly 
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reduced passive permeability. However, efflux transporters increase the apparent permeability of 
these metabolites to a similar level as the passive permeability of the parent drug. Therefore, the 
hepatic transporters affect the extent of excretion of carboxylic acid metabolites over the
basolateral membrane in the systemic circulation or over the apical membrane in bile.
Due to the membrane-barrier that restricts disposition of hydrophilic drug metabolites, the 
understanding of the uptake and efflux transporters in drug metabolite transport is an important 
and emerging topic.129 Permeability-limited disposition does not only determine the systemic 
exposure and excretion routes for metabolites but also affects their intracellular concentrations, 
which might differ drastically from the systemic concentrations.76 The intracellular hepatic 
concentrations are important factors when evaluating possible drug-drug interactions or hepatic 
toxicity of drug metabolites. For example, the evaluation of a CYP-mediated drug interaction 
based on the systemic concentration of a drug or drug metabolite might underestimate the 
magnitude of the interaction, if transporters contribute to the hepatic accumulation of the 
drug.76,130 The concentration of a drug can be multiple folds higher in the hepatic tissue than in 
the systemic circulation. Although measuring hepatic concentrations in humans is infeasible, 
some data arise from positron-emission tomography imaging experiments. These data depict the 
magnitude of transporter-mediated hepatic accumulation of drugs in humans. For example, the
human OATP substrates telmisartan and erlotinib concentrate over 10- and 40-fold, respectively, 
in the liver in comparison to blood in humans.131,132 Data on the accumulation of drug metabolites 
in the liver are available only from animal studies. For example, sorafenib glucuronide reaches 
over 300-fold higher concentrations in the mouse liver than in plasma, which illustrates the effect 
of the membrane-barrier on disposition of hydrophilic drug metabolites in vivo.133
The effects of metabolism related changes and drug transporters on the excretion of drug 
metabolites are summarized in Table 4.
Table 4. Disposition of drug metabolites derived from oxidation, conjugation and hydrolysis 
reactions. Typical metabolism related changes in the intrinsic molecular properties of a 
drug and effects of different factors on the disposition of these metabolites are indicated. 
The clearance terms are visualized in Figure 3 and defined in Equations 2-4.5,111-113,134
Metabolic 
reaction 
Typical 
biotransformation 
Changes in 
intrinsic 
molecular 
properties 
Disposition 
mechanism 
Systemic 
exposure 
Factors 
contributing 
to systemic 
clearance 
Excretion 
route 
Oxidation Hydroxylation, 
dealkylation 
Decrease of 
0-2 logP 
units 
 
Increase of 
10-20 Å2 in 
PSA 
Passive, if 
the parent is 
highly 
permeable 
(logD > 0, 
PSA < 75 
Å2) 
 
Presumable 
and 
proportional 
to fraction 
metabolized 
via this route 
2nd generation 
metabolism 
reactions, 
CLr,  fu 
Depends on 2nd 
generation 
metabolites, 
urine if high fu 
Conjugation, 
hydrolysis 
Glucuronidation, 
sulfation,  
ester hydrolysis 
Decrease of 
2-5 logP 
units 
 
Increase of 
~100 Å2 
PSA 
(glucuronic 
acid) 
 
A negative 
charge 
Transporter 
mediated 
Variable 
from 
negligible to 
high 
Hepatic 
uptake and 
efflux 
transporters 
(CLinflux, 
CLefflux and 
CLefflux,bile) 
 
Renal 
transporters 
(CLsec) 
fu 
Urine if high 
hepatic CLefflux, 
low Clinflux and 
high fu 
 
Bile if high 
hepatic CLinflux 
and CLefflux,bile 
 
Urine and bile if 
CLinflux < CLefflux 
≈ CLefflux,bile 
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2.3 Transporter-mediated disposition of glucuronide metabolites
Glucuronide metabolites of drugs can be classified in either ECCS Class 3A or 3B based on their 
properties: a negative charge, low permeability and low metabolism. Thus, the MW (> 400 Da or 
< 400 Da) might affect their disposition via either urine or bile. However, glucuronides are formed 
intracellularly, which implicates that hepatic efflux transporters (CLefflux and CLefflux,bile) control 
the efflux from the hepatocytes, and only if CLefflux is high, the hepatic CLinflux also contributes to 
the systemic exposure and clearance (Equation 4). In such cases, hepatic OATs and OATPs, in 
addition to the renal OATs, might play an important role in the systemic clearance of glucuronides 
(Table 2).
2.3.1 Efflux transporters in the excretion of glucuronides
In vivo evidence for the identification of individual transporters that affect the disposition of 
glucuronide metabolites in humans is scarce. The lack of in vivo reports is mostly due to
difficulties in attributing any drug-drug interactions that involve glucuronide metabolites to the
level of an individual efflux transporter. In addition, the effects of genotypes causing changes in
the activity of efflux transporters in vivo are either rarely reported or have not correlated 
significantly with the disposition of glucuronides.135 Finally, specific substrates among 
glucuronide metabolites or specific transporter inhibitors and inducers are currently 
unavailable.69,125,136 Therefore, the in vivo investigations are highly limited to reveal any
contribution of specific transporters to the disposition of glucuronides. An exception is the rare 
Dubin–Johnson syndrome that is caused by inactivating mutations in MRP2, which result in a 10-
to 100-fold increase in the plasma concentration of bilirubin glucuronide that is normally excreted 
in bile by MRP2.137 In addition, a non-coding variant of ABCC2, encoding MRP2, has been 
identified to correlate with the plasma levels of food-derived genistein and dihydrogenistein 
glucuronides in a study of 18 Japaneses.138 However, the most of the direct evidence of human 
efflux transporters that contribute to disposition of glucuronide drug metabolites currently comes 
from in vitro experiments.
Strong evidence from in vitro human and in vivo animal studies supports that hepatic and 
intestinal MRP2 and MRP3 are the main transporters for glucuronide metabolites of 
drugs.125,139,140 Growing evidence has revealed that MRP4 and BCRP are also involved in the 
transport of glucuronide conjugates.120,123,125,133,141-145 P-gp, on the other hand, is unlikely to play 
a role in the disposition of conjugated drug metabolites such as glucuronides, even if this 
transporter is one of the most important drug transporter.7,125 This negligible role of P-gp is mostly 
attributed to its repulsion of negatively charged and hydrophilic compounds, and specificity 
toward more lipophilic and cationic or neutral molecules.7,146
MRP2, MRP3, MRP4 and BCRP are important efflux transporters in drug disposition, as 
discussed in Section 2.1.4. The ABC transporter family contains almost 50 different proteins, 
although so far only proteins from the ABCC family and ABCG2, BCRP, have been identified to 
transport organic anions.67 Thus, it is possible that other glucuronide efflux transporters remain to 
be found. In fact, knockout animal studies have revealed that Mrp2, Mrp3, Mrp4 and Bcrp do not 
always fully explain the excretion of glucuronides over the hepatic apical or basolateral 
membranes, which indicates that unknown transporters might be involved in the excretion of 
glucuronide metabolites.133,147-149
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Most MRPs other than MRP2-4 are expressed ubiquitously in several tissues or at low mRNA 
levels in the liver.85,150 However, some studies have reported rather high protein expression of 
MRP1, MRP5 and MRP6 in the liver.83 No ideal substrate has been reported for MRP6 so far, and 
an unsuccessful attempt to study the transport of glucuronide conjugates by MRP6 is reported in 
a sub-study of this thesis (III). Therefore, the contribution of MRP6 to the transport of 
glucuronides is currently unknown.151,152 MRP5 transports small anionic compounds, and 
methotrexate glucuronide has been reported as a low affinity substrate for this transporter.153
However, it remains to be investigated whether MRP5 plays a role in the disposition of 
glucuronides. Finally, MRP1 transports glucuronide conjugates in vitro, and a study employing 
Mrp1-knockout mice reported that after oral administration of kaempferol its glucuronide 
conjugates were almost 10-fold less abundant in the systemic circulation in comparison to wild 
type mice.154,155 The significance of MRP1, MRP5 and MRP6 in the disposition and transport of 
glucuronide metabolites of drugs should be clarified in future studies.
It is not a coincidence that MRPs transport glucuronide conjugates, since mostly only organic 
anions have been discovered so far as the substrates for these transporters.85 In addition, MRP2 
and MRP3 are expressed rather specifically and highly in the liver, in comparison to other tissues, 
and are localized to the opposite membranes of hepatocytes (Figure 5), which allows them to 
function as important physiological backup routes for each other.83,139,140,150 The substrate 
specificity of MRP2, MRP3 and MRP4 overlaps considerably.85,125,139 In particular, substrates of 
MRP2 and MRP3 overlap significantly, whereas MRP4 specifically transports cyclic nucleotides 
such as cAMP and cGMP that are rather small anionic compounds.140,153 However, MRP4 is 
capable of transporting larger anions, such as estradiol-17β-glucuronide and 
dehydroepiandrosterone sulfate, similarly to MRP2 and MRP3. Therefore, it is impossible to draw 
conclusions on the factors that affect substrate recognition of these transporters. MRP2, but not 
MRP3, transports glutathione conjugates of drugs, indicating that MRP2 might transport larger 
MW compounds than MRP3 or MRP4.85,125,139 Finally, BCRP accepts both sulfate and 
glucuronide conjugates as well as other versatile structures as substrates, but aromatic rings and 
their effect on flatness of the structure are important properties for them.125,156 Thus, some 
substrates of MRPs might not be transported by BCRP. In addition, the charge of a compound is 
not crucial for BCRP in contrast to MRPs that tend to transport anionic compounds.85,156
2.3.2 Mechanistic studies on the effect of efflux transport on glucuronide 
disposition
Most of the evidence for glucuronide transporters and their mechanistic effects on glucuronide 
disposition has emerged from animal studies, particularly from knockout mice studies 
(summarized in Table 5). Additionally, multiple in vitro studies on human efflux transporters and 
their transport of glucuronide metabolites have been reported.120,123,125,133,141-145 However, 
comprehensive studies that compare the transport properties of several efflux transporters side by 
side in the transport of several glucuronide conjugates are lacking. In particular, studies that 
accurately characterize transport kinetics of different human efflux transporters, which is crucial 
for estimating the fractional contribution of individual transporters, are rare in the current 
literature.125,157
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Table 5. Summary of animal studies that investigated disposition of glucuronide metabolites of 
drugs and drug-like compounds in Mrp2-/--, Mrp3-/--, Mrp4-/--and Bcrp-/--knockout mice 
or Mrp2-deficient rats. Values are related to the respective wild type strains and 
represent either the area under the curve (AUC) or single plasma concentrations 
(perfusate and plasma), cumulative excretion (bile) or hepatic absolute concentrations 
or relative amounts (liver), but not rates of excretion.
Metabolite 
Strain and 
administration route of 
the parent compound 
Liver 
Perfusate or 
Plasma 
Bile 
4-methylumbelliferone-G148,149,158,159 Mrp2-deficient rats (IPL) NR 6× ↑ 70×↓ 
 Bcrp-/- mice (ISPL) 2× ↑ ↔ 2×↓ 
 Mrp2-/- mice (ISPL) ↔ ↔ 2×↓ 
 Mrp3-/- mice (ISPL) 2× ↑ 4×↓ 5× ↑ 
 Mrp4-/- mice (ISPL) ↔ ↔ ↔ 
 Mrp3-/- mice (oral) NR 4× ↓ NR 
4-methyl-esculetin-G160 Bcrp1-/- mice (oral) NR 2× ↑ NR 
 Bcrp1-/- mice (i.v.) NR 3× ↑ NR 
 Mrp2-/- mice (oral) NR 2× ↑ NR 
 Mrp2-/- mice (i.v.) NR 3× ↑ NR 
Acacetin-G161 Bcrp-/- mice (oral) ↔ 2× ↑ NR 
 Mrp2-/- mice (oral) 5× ↑ 6× ↑ NR 
Acetaminophen-G148,149,162,163 Mrp2-deficient rats (IPL) NR 2×↑ 340×↓ 
 Mrp3-/- mice (i.v.) 20×↑ 10×↓ 10×↑ 
 Bcrp-/- mice (ISPL) ↔  ↔ 3×↓ 
 Mrp2-/- mice (ISPL) 3×↓ 2×↑ 3×↓ 
 Mrp3-/- mice (ISPL) 6×↑ 5×↓ 7×↓ 
 Mrp4-/- mice (ISPL) ↔  ↔ ↔ 
Bilirubin-G (endogenous)164 Mrp2-/- mice NR 4× ↑ 4× ↓ 
 Mrp3-/- mice NR ↔ 2× ↓ 
 Mrp2;Mrp3-/- mice NR ↔ 11× ↓ 
Bisphenol-A-G158 Mrp3-/- mice (oral) NR 10× ↓ NR 
Clopidogrel-G165 Mrp3-/- mice (oral) 
liver/plasma 
ratio 11×↑ NR NR 
Diclofenac-G147,166 Bcrp1-/- mice (i.v.) 2× ↑ ↔ 2×↓ 
 Mrp2-/- mice (i.v.) ↔ 6× ↑ 2×↓ 
 Bcrp1;Mrp2-/- mice (i.v.) 2× ↑ 24× ↑ 4×↓ 
 Mrp3-/- mice (i.v.) ↔ 2×↓ NR 
 Bcrp1;Mrp3-/- mice (i.v.) ↔ 2×↓ NR 
 Mrp2;Mrp3-/- mice (i.v.) ↔ 2×↓ NR 
 
Bcrp1;Mrp2; Mrp3-/- mice 
(i.v.) 3× ↑ ↔ NR 
 Bcrp1-/- mice (i.v.) NR 3× ↑ ↔ 
 Mrp3-/- mice (i.v.) ↔ 6×↓ ↔ 
E3040-G158,167 Mrp2-deficient rats (i.v.) NR 12× ↑ 4× ↓ 
 Mrp3-/- mice (oral) NR 22× ↓ NR 
Ethinylestradiol-G168 Bcrp1-/- mice (i.v.) NR 2× ↑ NR 
 Bcrp1-/- mice (oral) NR 2× ↑ NR 
 Mrp2-/- mice (i.v.) NR 24× ↑ NR 
 Mrp2-/- mice (oral) NR 46× ↑ NR 
Etoposide-G169 Mrp2-/- mice (i.v.) 2×↓ 2× ↑ NR 
 Mrp3-/- mice (i.v.) ↔ ↔ NR 
 Mrp2;Mrp3-/- mice (i.v.) 8× ↑ ↔ NR 
Ezetimibe-G170 Bcrp1-/- mice (oral) ↔ NR ↔ 
 Bcrp1;Mrp2-/- mice (oral) 70× ↑ 270× ↑ 40×↓ 
 Mrp2-/- mice (oral) 29× ↑ NR 2×↓ 
 Mrp3-/- mice (oral) 2×↓ 14×↓ (portal vein) 3×↓ 
Gemfibrozil-G158 Mrp3-/- mice (oral) NR 2× ↓ NR 
Genistein-G171,172 Bcrp1-/- mice (oral) NR 14× ↑ NR 
 Bcrp1-/- mice (i.p.) NR 3× ↑ NR 
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 Bcrp-/- mice (oral) NR 7× ↑ NR 
Harmol-G148,149 Bcrp-/- mice (ISPL) NR NR 16×↓ 
 Mrp2-/- mice (ISPL) NR ↔ ↔ 
 Mrp3-/- mice (ISPL) NR NR ↔ 
 Mrp4-/- mice (ISPL) ↔ ↔ ↔ 
Kaempferol-G155 Bcrp1-/- mice (oral) NR 3× ↑ NR 
 Mrp2-/- mice (oral) NR 4× ↑ NR 
Morphine-3-G173,174 Mrp2-/- mice (i.p.) 3×↓ 2× ↑ 100×↓ 
 Mrp3-/- mice (i.p.) NR 14×↓ ↔ 
 Mrp3; Mrp4-/- mice (i.p.) NR 14×↓ NR 
 Mrp2;Mrp3-/- mice (i.p.) 13× ↑ 14×↓ 100×↓ 
 Mrp3-/- mice (i.p.) 5× ↑ 30×↓ 5× ↑ 
PhIP-G175 
Bcrp1;Mdr1a/b;Mrp2-/- 
mice (i.v.) NR 2×↓ 630×↓ 
Resveratrol-G176,177 Bcrp1-/- mice (oral) ↔ 2× ↑ NR 
 Mrp3-/- mice (oral) 2×↓ 10×↓ NR 
S-8921-G178 Mrp2-deficient rats (i.v.) 5× ↑ 3× ↑ ↔ 
 Bcrp-/- mice (i.v.) NR ↔ ↔ 
Sorafenib-G133 Mrp2-/- mice (oral) 3× ↑ 350× ↑ 12×↓ 
 Mrp3-/- mice (oral) ↔ ↔ NR 
 Mrp4-/- mice (oral) ↔ ↔ NR 
 Mrp3;Mrp4-/- mice (oral) ↔ ↔ NR 
E3040 = 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridymethyl)benzothiazole, G = glucuronide,                          
i.p. = intraperitoneal, IPL= isolated perfused liver, ISPL = in situ perfused liver, i.v. = intravenous, NR = not reported, 
PhIP = 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, S-8921 = methyl 1-(3,4-dimethoxyphenyl)-3-(3-
ethylvaleryl)-4-hydroxy-6,7,8-trimethoxy-2-naphthoate 
The data in Table 5 clearly demonstrate that Mrp2, Mrp3 and Bcrp contribute to the disposition 
of glucuronide metabolites according to their location in hepatocytes and enterocytes, namely 
Mrp3 in the basolateral and Mrp2 and Bcrp in the apical membranes. Data in Table 5 indicate that 
Mrp4 does not contribute to the disposition of glucuronides of 4-methylumbelliferone,
acetaminophen, harmol, morphine or sorafenib. Morphine-3-G is not an MRP4 substrate, whereas 
no data are available for the glucuronides of acetaminophen and harmol.149,174 On the other hand, 
it was found within this thesis that 4-methylumbelliferone-G is even a better substrate for MRP4 
than for MRP3 (I), although only the knockout of Mrp3 affected the hepatic excretion of 4-
methylumbelliferone-G in mice (Table 5). Finally, MRP4 transports sorafenib-G similarly to 
MRP3 but the knockout of either transporter did not affect the excretion of this metabolite, 
indicating contribution of unknown basolateral transporters.133
The expression of MRP4 is low in the human liver and possibly also in the mouse liver.77,83
Nevertheless, the decreased basolateral excretion of the sulfate metabolites of 4-
methylumbelliferone, acetaminophen and harmol from the livers of Mrp4-/- mice in comparison 
to the wild type mice strongly suggests that a functional Mrp4 is present in the wild type mouse 
livers.149 The discrepancies between the aforementioned in vivo mice and in vitro human studies 
remain to be explained, and the significance of hepatic MRP4 in the disposition of glucuronide 
metabolites should be studied in more detail. In addition, only a few studies have investigated 
interspecies differences between human and animal efflux transporters, and thus no conclusions 
can be made about the similarities in the substrate preference between mouse and human MRPs.179
Another clear conclusion from the data in Table 5 is the notable overlapping substrate 
specificity between Mrp2 and Mrp3. The absence of hepatic Mrp2 shifts the excretion pathway 
from biliary to systemic that is mostly mediated by Mrp3. For example, the knockout of Mrp2
doubles the systemic exposure of etoposide-G and decreases its hepatic concentration to half, 
while the Mrp3-knockout does not affect the respective values (Table 5).169 The double knockout 
of Mrp2 and Mrp3, on the other hand, increases the hepatic amount of etoposide-G to an eight-
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fold higher level than in the wild type or Mrp3 knockout mice, while this knockout does not affect 
the systemic concentration. Such observations clearly demonstrate the compensating roles of 
Mrp2 and Mrp3 for each other. If both transporters are absent, the intracellular amounts of 
glucuronide metabolites increase at least several fold, depending on other transporters that carry 
the metabolites. It should be noted that upregulation of hepatic Mrp3 is usually observed in Mrp2-
knockout mice and Mrp2-deficient rats.159,169 This upregulation may partly explain the higher 
basolateral excretion in knockout animals, or lower hepatic concentrations as in the case of
etoposide-G, compared to wild type animals. Finally, results from animal knockout studies should 
not be translated directly to humans or interpreted quantitatively, because of the upregulation of 
some transporters or differences in their basal expression levels and substrate specificities in 
animals in comparison to human tissues.157 Nevertheless, knockout studies provide mechanistic 
understanding on the effect of efflux transporters and to what extent they affect glucuronide 
metabolite disposition.
Efflux transporter knockout studies may help deduce the fraction excreted (fe) parameter for a 
specific transporter. Furthermore, fe can be used to estimate the effect of a putative transporter 
inhibitor (I with an inhibition constant Ki) on the relative change of metabolite exposure (fold∆) 
in blood, tissue or bile according to Equation 5.180 If the whole pathway is knocked out ([I]>>Ki),
the subtracted form of Equation 5 can be employed. Knockout of pathways that have an fe value 
≤ 0.5 or their full inhibition would lead to a maximum of two-fold change in the exposure, not 
more. Because hepatic efflux transporters have considerable overlapping substrate specificities in 
the transport of glucuronide metabolites, Equation 5 might explain why drug-drug interactions or 
genotype effects have not been reported at the efflux transport level in humans. Furthermore, 
determination of fe to different human efflux transporters would demand comprehensive studies 
with human transporters in vitro and extrapolation of in vitro expression levels of transporters to 
in vivo with the aid of proteomics data.76 Thus, better understanding of different human efflux 
transporters in vitro is warranted.
(5) ?????? ???
??? ????????
? ????? ????
, if [I]>>Ki then ?????? ? ?????
2.3.3 Interplay of uptake and efflux transport in the disposition of glucuronide 
metabolites
The systemic clearance of glucuronide metabolites is controlled by the mechanisms presented in 
Equation 4. The metabolism of glucuronide conjugates is usually negligible, although acyl 
glucuronides with an ester bond might be prone to esterase-mediated cleavage.19,181 In addition, 
CLpassive of glucuronides is low and therefore Equation 4 is simplified to Equation 6.
(6) ??????? ?
????????? ??????????? ???
?????????? ?????????? ????
Efflux transporters are rarely specific, as discussed in Section 2.3.1. Furthermore, both the
apical and basolateral transporters exhibit substantially overlapping substrate specificity, 
implicating that in most cases both CLefflux and CLefflux,bile contribute to the hepatic excretion. Thus, 
the systemic exposure of a glucuronide metabolite is dependent on the fe values of both the apical 
and basolateral efflux transporters. However, as Equation 6 indicates, CLinflux is the major factor 
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contributing to CLint,h, and thus the net secretion from the liver to the systemic circulation is related 
to CLinflux/CLefflux. Together, the disposition of glucuronide metabolites is not only mediated by 
the efflux transporters but also by the uptake transporters of which the most important in the liver 
are OATP1B1, OATP1B3, OATP2B1, OAT2 and the emerging OAT7, as discussed in Section 
2.1.4. Finally, the renal uptake transporters, particularly OAT1 and OAT3, contribute to CLsec,
and if CLr is high or similar to the hepatic clearance, the renal transporters should also be 
considered in the disposition of glucuronides.
A representative example of the impact of different mechanisms on the disposition of a 
glucuronide conjugate is provided by the mechanistic studies with E3040, a small molecular 
inhibitor of 5-lipoxygenase and thromboxane A2 synthetase, and its glucuronide metabolite, 
E3040-G, in rats. E3040-G is a substrate for both Mrp2 and Mrp3 (Table 5), and hepatic uptake 
transporters have a major contribution to its uptake into rat hepatocytes.182 After intravenous 
administration of E3040 to rats, 95% of the formed glucuronide was excreted in bile and only 5% 
in urine (Figure 6).167 The same amount of the glucuronide metabolite was excreted in bile also 
after intravenous administration of E3040-G, and its CLr was only 5% of the total plasma 
clearance, while no metabolism was found.182 This indicates that the hepatic uptake is responsible 
for 95% of the total plasma clearance of E3040-G. Mrp2-deficient rats had 71-fold lower 
CLefflux,bile and similar CLr in comparison to the wild type rats, while the cumulative amount of 
biliary and urinary excreted E3040-G was only 5-fold lower and 15-fold higher, respectively. 
Figure 6 Schematic presentation of the disposition of E3040-G in rats. E3040 or E3040-G were 
administered intravenously to wild type (A, C) or Mrp2-deficient rats (B). Clother represents 
other metabolic clearances, which account for about 70% of the total clearance in the cases 
of A and B.158,167,182
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The data of E3040-G elegantly illustrate that the systemic exposure and subsequent urinary 
excretion is not only determined by the relative fe of the hepatic basolateral and apical efflux 
transporters but by the net clearance, CLinflux/CLefflux, over the basolateral membrane. If the net 
clearance is high, even low CLefflux,bile will significantly contribute to the cumulative biliary 
excretion of the compound (Figure 6).
The interaction of glucuronide metabolites with hepatic OATP1B1, OATP1B3, OATP2B1 
and OAT2, as well as renal OAT1 and OAT3 is an emerging research topic, although the currently 
available data are still scarce.120,123,124,129,183,184 However, similarly to knockout of efflux 
transporters in mice, knockout of the homological mouse transporters of hepatic OATPs have 
been developed, and a few studies have investigated disposition of glucuronide metabolites in 
these mice. It should be noted that direct orthologues of human OATP1B1 and OATP1B3 are 
absent from the mouse liver.179
Oral administration of regorafenib to Oatp1b2−/− mice resulted in a nine-fold higher plasma 
AUC of regorafenib glucuronide in comparison to wild type mice.185 Furthermore, the plasma 
AUC of sorafenib glucuronide was increased 72-fold in Oatp1a/1b−/− mice in comparison to wild 
type mice after administration of oral sorafenib.133 Remarkably, further knockout of Mrp2 in 
Oatp1a/1b−/− mice resulted in a total of 900-fold higher plasma AUC of sorafenib glucuronide in 
comparison to wild type mice. Moreover, the sorafenib-G concentration ratio of liver to plasma 
was reduced from 350 in wild type mice to about 1 in Mrp2;Oatp1b2−/− mice. These observations 
indicate that in the absence of CLinflux, sorafenib-G is completely transported via the hepatic 
basolateral membranes to the systemic circulation and no accumulation of the metabolite into the 
liver occurs. These studies further confirm the mechanistic importance of the hepatic CLinflux in 
determining the systemic exposure of glucuronide metabolites.
Hepatic uptake does not only affect the hepatic derived glucuronides but also glucuronides 
formed in enterocytes and excreted over the basolateral membranes to blood after oral drug 
administration. Zeng and coworkers infused glucuronides of several flavonoids, including 
apigenin, biochanin A, chrysin and genistein, into the portal vein of rats and found that the liver 
extracted 60-100% of the glucuronides, which indicates excessive transporter-mediated uptake 
into liver.186 Finally, some glucuronide metabolites have been identified as OAT substrates. For 
example, cabotegravir and morinidazole glucuronides are OAT3 substrates and diclofenac 
glucuronide is a substrate for OAT1, OAT3 and OAT4.123,183,184 These three transporters may 
contribute to CLr of the aforementioned glucuronide metabolites. In addition, hepatic OAT2 and 
OAT7 were only recently identified to contribute to the active uptake of anionic drugs into the 
liver.74 Thus, future research of their impact on glucuronide metabolites is warranted.
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3 Aims of the study
The main aims of this thesis were to identify molecular mechanisms that control the excretion of 
drug metabolites from the human liver and intestine, and whether these mechanisms can explain 
the extent of systemic exposure, urinary excretion and biliary excretion of hydrophilic drug 
metabolites. Specific aims were set to study the activity of human hepatic and intestinal efflux 
transporters MRP2, MRP3, MRP4, BCRP and P-gp in the transport of glucuronide conjugates 
that are typical hydrophilic drug metabolites, which require carrier-mediated mechanisms for their 
excretion from tissues.
For each sub-study, a set of glucuronide metabolites of drugs or drug-like compounds was 
selected and their transport by human MRP2, MRP3, MRP4, BCRP and P-gp was compared in 
the activity and transport kinetic assays:
I Planar ring containing and mostly small MW glucuronides, including 1-
hydroxypyrene, 1-naphthol, 4-methylumbelliferone glucuronides and two 
glucuronides of enantiomeric R- and S-propranolol.
II Small MW glucuronides of nicotine and of its oxidative metabolites cotinine and 
trans-3’-hydroxycotinine.
III High MW glucuronides of estrogens including estradiol, estriol and estrone.
IV High MW glucuronides of androgens including dehydroepiandrosterone, 
epitestosterone, testosterone as well as the glucuronides of its metabolites 
androsterone and etiocholanolone.
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4 Materials and Methods
The key materials and methods of this thesis are presented in this section. Full details are described 
in Publications I-IV.
4.1 Materials
The glucuronides investigated in this thesis, including their key intrinsic molecular properties 
MW, logD7.4 and PSA, which were calculated in MarvinSketch (version 19.15, ChemAxon Ltd.),
are presented in Table 6. The 3D conformations were generated in Chem3D and the MM2 function 
was used to minimize the energy of structures (version 17.0.0.206, PerkinElmer Informatics Inc.).
Table 6. Molecular structures and the intrinsic molecular properties of the glucuronides 
investigated in this thesis. Hydrogen atoms, except polar hydrogens, are omitted for
clarity. G stands for glucuronide.
 
1-naphthol-G 
MW = 320.3 Da, logD7.4 = -2.64, PSA = 116 Å2 
 
1-hydroxypyrene-G 
MW = 394.4 Da, logD7.4 = -1.24, PSA = 116 Å2 
 
4-methylumbelliferone-G 
MW = 352.3 Da, logD7.4 = -3.65, PSA = 143 Å2 
 
R-propranolol-G 
MW = 435.5 Da, logD7.4 = -1.34, PSA = 138 Å2 
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S-propranolol-G 
MW = 435.5 Da, logD7.4 = -1.34, PSA = 138 Å2 
 
Nicotine-G 
MW = 339.4 Da, logD7.4 = -5.29, PSA = 114 Å2 
 
Cotinine-G 
MW = 353.4 Da, logD7.4 = -6.06, PSA = 131 Å2 
 
Trans-3’-Hydroxycotinine-G 
MW = 368.4 Da, logD7.4 = -5.47, PSA = 150 Å2 
 
Estradiol-3-G 
MW = 448.5 Da, logD7.4 = -1.63, PSA = 137 Å2 
 
Estradiol-17β-G 
MW = 448.5 Da, logD7.4 = -1.04, PSA = 137 Å2 
Estriol-3-G 
MW = 464.5 Da, logD7.4 = -2.70, PSA = 157 Å2 
Estriol-16α-G 
MW = 464.5 Da, logD7.4 = -2.17, PSA = 157 Å2 
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Estrone-3-G 
MW = 446.5 Da, logD7.4 = -1.06, PSA = 134 Å2 
Androsterone-G 
MW = 446.6 Da, logD7.4 = -1.07, PSA = 134 Å2 
 
Dehydroepiandrosterone-G 
MW = 465.6 Da, logD7.4 = -1.48, PSA = 134 Å2 
 
Epitestosterone-G 
MW = 464.6 Da, logD7.4 = -1.42, PSA = 134 Å2 
 
Etiocholanolone-G 
MW = 466.6 Da, logD7.4 = -1.07, PSA = 134 Å2 
Testosterone-G 
MW = 464.6 Da, logD7.4 = -1.42, PSA = 134 Å2 
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Androsterone-G, estradiol-17β-G, estriol-3-G, estriol-16α-G, dehydroepiandrosterone-G,
testosterone-G, 1-naphthol-G and 4-methylumbelliferone-G were from Sigma-Aldrich, whereas 
etiocholanolone-G was from Steraloids. Estradiol-3-G was from Cayman Chemical, whereas 
estrone-3-G, nicotine-G, cotinine-G and trans-3’-hydroxycotinine-G were from Toronto Research 
Chemicals. N-methyl-quinidine was acquired from Solvo Biotechnology. The glucuronide of 1-
hydroxypyrene was previously synthesized in-house.187 Epitestosterone-G was biosynthesized 
within this study using the human UGT2B7 as the catalyst, whereas R- and S-propranolol-G were 
biosynthesized within this study using the human UGT1A10 and UGT1A9, respectively, as the 
catalysts. The details of biosyntheses are reported in Publications I and IV.
Water-soluble cholesterol- RAMEB (randomly substituted methyl-β-cyclodextrin) complex 
was from Cyclolab Ltd. The source of protease inhibitors was typically cOmplete Ultra EDTA-
free protease inhibitor cocktail tablets from Roche.
4.2 Preparation of membrane vesicles for the efflux transport assays
Human efflux transporter cDNA-containing baculoviruses were employed to infect Sf9 insect 
cells for the production of recombinant transporter proteins. The construction and preparation of
recombinant baculoviruses for human MRP2, BCRP and P-gp has been reported earlier.188-190 The
preparation methods of baculoviruses for MRP3 and MRP4 are reported in Publication I. For one 
membrane vesicle batch of a transporter, a suspension culture of Sf9 cells, 800 to 1600 ml at a 
density of 1.6 × 106 cells per milliliter, were infected with 0.5 to 2.5 μl of the third passage (P3) 
baculovirus, containing the transporter cDNA, per milliliter of culture. The amount of virus 
employed for the cell infection was optimized to achieve high expression of each transporter. 
After the infection, the cells were cultured for 3 days, harvested and the cell pellets were stored at 
-20 °C.
For the control preparations (CTRL), cells were infected with either empty baculovirus (I and 
III) or baculovirus containing cDNA that encodes an inactive mutant of MRP3 (II and IV). The 
construction of baculovirus for the inactive MRP3 mutant, the expression of the protein and 
verifying its inactivity are reported in Publication II.
The protocol for the preparation of inside-out membrane vesicles was adapted from Chu and 
coworkers.191 For the membrane vesicle preparation, a cell pellet from 100 ml culture was placed 
on ice and resuspended in 15 ml of cold buffer (50 mM Tris hydrochloride pH 7.0 and 300 mM 
mannitol) containing protease inhibitors. After 45 min incubation on ice, the cells were collected 
by 10 min centrifugation at 1200 g and resuspended in 10 ml of cold TME-buffer (50 mM Tris 
hydrochloride pH 7.0, 50 mM mannitol, and 2 mM EGTA), homogenized by 40-80 strokes with 
a Dounce homogenizer with pestle B and incubated on ice for 60 min. Cell debris was removed 
by centrifugation for 10 min at 1200 g and the resulting supernatant was subjected to 75 min 
centrifugation at 100 000 g. The resulting pellet contained the membrane fraction of cells, which 
was resuspended in about 1 ml of TME-buffer and passed 20 times through a 27-gauge needle to 
form membrane vesicles. Finally, the total protein concentration of membrane vesicles was 
adjusted to 5 mg/ml with TME-buffer, followed by a snap-freeze in liquid nitrogen and transfer 
to -80 °C for storage.
BCRP, P-gp and their control (CTRL+C) vesicles were supplemented with additional 
cholesterol to enhance their transport activity as reported.192,193 For cholesterol supplementation, 
the membrane fraction was resuspended in 1-2 ml of TME-buffer with 2.5 mM 
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cholesterol/RAMEB complex, and this suspension was incubated for 20 min on ice with gentle 
mixing. Next, the suspension was diluted with TME-buffer and centrifuged again for 75 min at 
100 000 g, after which it was processed similarly to the other preparations.
4.3 Vesicular transport assays and data analyses
The vesicle-based transporter assay was employed to study efflux transport in this thesis.136 For
the assay, transporter vesicles were thawed at +37 °C, after which 20-50 μg of total vesicle protein 
per sample was mixed with transport assay buffer (60 mM KCl, 40 mM MOPS adjusted to pH 7.0 
with Tris-HCl and 6 mM MgCl2) including a pre-determined concentration of the compound to 
be studied, in a total volume of 50 μl. The stocks of glucuronide conjugates (Table 6) were 
prepared in either DMSO or water (nicotine glucuronides) at 50 mM, and the maximum final 
concentration of DMSO in the assays was 1%. Samples were prepared on a 96-well plate on ice 
and then placed on a 37 °C shaker at 500 rpm for 10 min.
The transport reactions were initiated by the addition of 25 μl of transport assay buffer 
containing 6 mM Mg-ATP (+ATP samples) or plain buffer (-ATP samples). Final concentrations 
of the assay components in the transport reaction were 60 mM KCl, 40 mM MOPS, 6 mM MgCl2,
4 mM Mg-ATP (only +ATP samples) and the final volume was 75 μl. The final concentrations of 
the glucuronides ranged from 1 to 10 μM in the single concentration assays, as indicated in the 
figure legends, or were several different concentrations in the case of the transport kinetic assays. 
The transport reactions were incubated at 37 °C and 500 rpm shaking for a pre-determined time 
(between 1 and 10 min, indicated in the figure legends), before reactions were terminated by the 
addition of 200 μl cold stop buffer (40 mM MOPS adjusted to pH 7.0 and 70 mM KCl). Finally, 
samples were transferred to a glass fiber filter plate (pore size 1.0 μm, from Merck Millipore) that 
was kept under vacuum, and an additional 200 μl of cold stop buffer was applied five times into 
wells of the filter plate.
After the samples had been washed, the filter plate was kept at room temperature for 1-2 hours 
for drying. To disrupt the vesicles and elute the compounds, 100 μl of elution solvent was applied 
into each well and the plate was placed on a shaker adjusted to 250 rpm for 30-60 min. Finally, 
sample eluates were collected to a new well plate by centrifuging the filter plate on the top of a 
collection plate for 2 min at 3 000 g. The elution solvents were 50% methanol containing 0.1% 
formic acid (I), 50% acetonitrile containing 0.1% formic acid (III), 75% methanol containing 
0.1% formic acid (IV), or 70% acetonitrile containing 10 mM ammonium acetate (II). In case of 
analysis with ultra-performance liquid chromatography connected to triple quadrupole mass 
spectrometry (UPLC-MS/MS), the elution solvent also contained an internal standard that was a 
glucuronide compound of a similar structure to the analyte (II-IV).
Each assay included triplicate samples for every data point and the mean value from a single 
experiment is presented with ± SD in the Results section. The transport kinetics included seven to 
eight different concentrations around the estimated Km value, and the transport reaction times were 
selected based on the pre-determined linear ranges of the transport (data reported in I-IV). To 
exclude solubility problems or other artifactual factors during the assay, the -ATP data were 
examined by plotting them against the concentrations of the compound investigated and a linear 
fit was ensured, which mostly resulted in R2 values over 0.99, but in a few cases R2 was 0.97-
0.98. The maximum determined solubility for androgen and estrogen glucuronides was 500 μM.
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The ATP-dependent transport kinetic data presented in the Results section were derived by 
subtracting the results of -ATP samples from +ATP samples, and the data represent mean ± 
combined SD of the subtracted values. The resulting transport rate (v) was fitted to either the 
Michaelis-Menten equation (Equation 7) or Hill’s equation (Equation 8) with least squares fit. 
Vmax, [S], Km, h and S50 are the maximum transport rate, substrate concentration, the Michaelis 
constant, the Hill coefficient and the concentration producing half-maximal transport rate, 
respectively. 
(7) ? ? ? ????? ??????? ????
(8) ? ? ? ?????? ????
?
????? ?????
4.4 Analytical methods
High performance liquid chromatography (HPLC) connected to a fluorescence (FL) detector was 
employed to quantify 1-naphthol-G, 1-hydroxypyrene-G, 4-methylumbelliferone-G, R- and S-
propranolol-G, as well as estradiol-17β-G. UPLC-MS/MS was employed for the quantification of 
the other compounds. External standard quantification was used for HPLC-FL analyses, whereas 
the internal standard method was employed for UPLC-MS/MS analyses. The HPLC-FL methods 
are reported in Publication I and UPLC-MS/MS methods in Publications II-IV. The HPLC-FL 
method for the analysis of N-methyl-quinidine has been reported elsewhere.190
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5 Results
This section summarizes the main results of Publications I-IV.
5.1 Functionality of the efflux transporters in this thesis
The correct transport activity of the human efflux transporters in the membrane vesicles for in 
vitro assays in this thesis was verified by employing the known MRP2-4 and BCRP substrate 
estradiol-17β-G and the P-gp substrate N-methyl-quinidine (Figure 7). 
Figure 7 The transport kinetics of MRP2, MRP3, MRP4, BCRP and P-gp. Well-characterized 
substrates of these transporters were employed. The transport reaction time was either 3 
min (MRP3, MRP4 and P-gp) or 6 min (MRP2 and BCRP). The solid lines represent fitting 
of the data. The P-gp transport data of N-methyl-quinidine have been reported earlier.194
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MRP2-mediated transport kinetics of estradiol-17β-G yielded a distinct sigmoidal curve, 
whereas the other transporters followed Michaelis-Menten kinetics (Figure 7). The type of 
transport kinetics as well as the derived kinetic values are in line with the reported literature values 
(Table 7), which verifies the correct functionality of the efflux transporters employed in the 
vesicular transport assays of this thesis.
Table 7. The derived kinetic constants for the data in Figure 7. The data were fitted to the 
Michaelis-Menten equation, except in the case of MRP2 Hill’s equation was employed.
Transporter Km (95% CI), μM 
Vmax (95% CI), 
pmol/min/mg 
total protein Literature values192,193,195-197 
Estradiol-17β-G 
MRP2 
S50 = 124 (108-139) 
h = 2.3 (1.9-2.7) 3520 (3180-3850) 
S50 = 105 μM, h = 2.9,  
Vmax = ~3000 pmol/min/mg total protein 
MRP3 30 (18-43) 148 (126-169) Km = 26 μM, Vmax = 76 pmol/min/mg total protein 
MRP4 67 (38-95) 243 (194-292) Km = 30 μM, Vmax = 102 pmol/min/mg total protein 
BCRP 58 (46-69) 678 (621-735) Km = 45 μM, Vmax = 700 pmol/min/mg total protein 
N-methyl-quinidine 
P-gp 11 (7.7-14) 557 (509-604) Km = 4 μM, Vmax = 657 pmol/min/mg total protein 
5.2 Transport of small glucuronides (I)
The transport of glucuronides of 4-methylumbelliferone, 1-naphthol, 1-hydroxypyrene, R- and S-
propranolol by MRP2-MRP4 and BCRP was assayed at a single substrate concentration (Figure 
8). The results indicated that MRP4 is highly active in the transport of the three glucuronides with 
planar aromatic rings, namely 4-methylumbelliferone-G, 1-naphthol-G, 1-hydroxypyrene-G,
whereas propranolol glucuronides were transported only by MRP3, although at low rates. 
Furthermore, the transport of 4-methylumbelliferone-G, 1-naphthol-G and 1-hydroxypyrene-G
was observed by MRP3 and BCRP, even though the control vesicles for BCRP were active in the 
case of 4-methylumbelliferone-G and 1-naphthol-G. The MRP2-mediated transport of 4-
methylumbelliferone-G, 1-naphthol-G and 1-hydroxyprene-G was too low to be characterized in 
the transport kinetic assays. In the case of BCRP with 4-methylumbelliferone-G or 1-naphthol-G,
the difference in the transport activity between control and BCRP vesicles was too low to reveal 
accurately the real contribution of BCRP, particularly at a higher concentration or in the presence 
of a specific BCRP inhibitor (data shown in Publication I).
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Figure 8 Single concentration transport of the small glucuronides. The concentration of the 
glucuronides was 10 μM and the transport reaction incubation time was 5 min.
Results from the transport kinetic experiments with MRP3, MRP4 and BCRP (Figure 9) were 
fitted to the Michaelis-Menten equation (Table 8). The MRP4-mediated transport of 4-
methylumbelliferone-G, 1-naphthol-G and 1-hydroxypyrene-G occurred at higher Vmax and lower 
Km values in comparison to MRP3, whereas the MRP3-mediated transport kinetics of propranolol 
glucuronides resulted in high Km values (Table 8). A clear difference was observed between R-
and S-propranolol-G in the transport kinetic study (Figure 9) similarly to the single substrate 
concentration assay (Figure 8), namely that the R-isomer is a better substrate for MRP3 than the 
S-isomer. The BCRP-mediated transport of 1-hydroxypyrene-G occurred at a similar Km value to 
MRP3 and MRP4 but at a much higher Vmax value.
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Figure 9 The transport kinetics of the small glucuronides. The transport reaction times were 3 min 
for MRP4 and 5 min for MRP3 in the transport of 4-methylumbelliferone-G, 10 min for 
MRP3 in the transport of propranolol glucuronides and 1 min in the other cases. The solid 
lines represent fitting of the data to the Michaelis-Menten equation.
Table 8. The derived kinetic constants for the transport kinetic data in Figure 9.
Substrate Km (95% CI), μM Vmax (95% CI), pmol/min/mg total protein 
MRP3 
1-naphthol-G 98.2 (45.0-151) 192 (150-234) 
1-hydroxypyrene-G 8.08 (5.64-10.5) 481 (440-523) 
4-methylumbelliferone-G 278 (178-377) 191 (153-229) 
R-propranolol-G 154 (117-192) 110 (98.0-122) 
S-propranolol-G 315 (108-522) 104 (108-522) 
MRP4 
1-naphthol-G 12.7 (7.64-17.7) 1110 (1030-1180) 
1-hydroxypyrene-G 3.21 (1.90-4.53) 1510 (1320-1690) 
4-methylumbelliferone-G 168 (139-197) 778 (712-844) 
BCRP 
1-hydroxypyrene-G 10.5 (8.55-12.3) 4430 (4180-4670) 
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5.3 Transport of the glucuronide metabolites of nicotine (II)
Nicotine-G and the glucuronides of two oxidation metabolites of nicotine, cotinine-G and trans-
3’hydroxycotinine-G, were assayed in the vesicular transport assay (Figure 10). None of the 
transporters studied were active toward nicotine-G or cotinine-G, whereas only MRP3 actively 
transported trans-3’hydroxycotinine-G. The data from MRP3 transport kinetics of trans-
3’hydroxycotinine-G were fitted to the Michaelis-Menten equation, which resulted in an 
estimated Km value of 728 (411-1050 95% CI) μM and Vmax of 501 (383-619 95% CI) 
pmol/min/mg total protein (Figure 10). 
Figure 10 Single concentration transport of nicotine-G, cotinine-G and trans-3’hydroxycotinine-G, 
and MRP3 transport kinetics of trans-3’-hydroxycotinine-G. The single concentration 
transport reactions included 5 μM of the compound. The transport reactions were incubated 
for 10 min. The incubation time in MRP3 transport kinetic assay was 10 min, and the solid 
line represents fitting of the data to the Michaelis-Menten equation.
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5.4 Transport of estrogen glucuronides (III)
BCRP was highly active in the transport of estrone-3-G and estradiol-3-G, while substantially 
weaker transport activity of BCRP was found toward both estriol glucuronides (Figure 11). 
Interestingly, the BCRP-mediated transport activity increased in the same order as the logD7.4
values of the estrogen glucuronides investigated, which are -2.70, -2.17, -1.63 and -1.06 for 
estriol-16α-G, estriol-3-G, estradiol-3-G and estrone-3-G, respectively (Table 6). MRP2 and 
MRP3 transported all the estrogen glucuronides tested, while MRP4 was clearly active only 
toward estriol-16α-G (Figure 11). The transport activity of P-gp was similar to the control 
vesicles, CTRL+C.
Figure 11 Single concentration transport of the estrogen glucuronides. The concentration was 10 μM 
in the assays that were incubated for 4 min.
The kinetic analyses revealed clear differences between MRP2 and MRP3 in the transport of 
all four estrogen glucuronides (Figure 12). The MRP3-mediated transport saturated at low 
concentrations, which resulted in Km values below 20 μM, whereas the MRP2-mediated transport 
saturated at higher concentrations and resulted in Km values between 200 and 800 μM (Table 9). 
Similar to the single concentration transport assays (Figure 11), BCRP transported estrone-3-G
and estradiol-3-G at high Vmax values in comparison to estriol glucuronides (Figure 12 and Table 
9). Finally, the MRP4-mediated transport of estriol-16α-G resulted in a Km value of 65 μM, which 
is over 10-fold higher than the corresponding value for MRP3 but over 10-fold lower in 
comparison to MRP2.
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Figure 12 The transport kinetics of the estrogen glucuronides. The incubation time in the transport 
reactions was 2 min, except 1 min for the MRP3-mediated transport of estradiol-3-G, and 6 
min for MRP2-mediated transport of estrone-3-G and estriol-3-G, as well as BCRP-
mediated transport of estriol-3-G. The lines represent fitting of the data to the Michaelis-
Menten equation. Only error bars above data points are shown for clarity.
Table 9. The derived kinetic constants for the transport kinetic data in Figure 12.
Substrate Km (95% CI), μM Vmax (95% CI), pmol/min/mg total protein 
MRP2 
Estrone-3-G 241 (198-285) 884 (810-960) 
Estradiol-3-G 180 (130-230) 1700 (1510-1900) 
Estriol-3-G 791 (585-997) 1800 (1470-2120) 
Estriol-16α-G 773 (532-1010) 6440 (4930-7940) 
MRP3 
Estrone-3-G 7.28 (5.06-9.50) 182 (167-198) 
Estradiol-3-G 2.83 (1.76-3.91) 260 (240-280) 
Estriol-3-G 18.2 (14.7-21.6) 441 (411-471) 
Estriol-16α-G 4.82 (2.82-6.82) 195 (174-216) 
BCRP 
Estrone-3-G 73.8 (62.1-85.5) 9310 (8810-9810) 
Estradiol-3-G 80.9 (39-123) 7910 (6700-9130) 
Estriol-3-G 1020 (621-1418) 4410 (3140-5690) 
Estriol-16α-G 22.4 (11.1-33.6) 974 (861-1090) 
MRP4 
Estriol-16α-G 64.8 (48.4-81.2) 522 (479-565) 
Estrone-3-G Estradiol-3-G Estriol-3-GEstriol-16α-G
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5.5 Transport of androgen glucuronides (IV)
Neither BCRP, MRP4 nor P-gp transported any of the five androgen glucuronides tested, whereas 
MRP2 and MRP3 were active toward them, even though at variable rates (Figure 13). MRP3 was 
clearly more active than MRP2 in the transport of androsterone-G, epitestosterone-G and 
etiocholanolone-G (Figure 13). All these structures have their glucuronic acid pointing to the 
opposite direction than the methyl groups of the androgen scaffold (Table 6). On the other hand, 
the activities of MRP2 and MRP3 in the transport of dehydroepiandrosterone-G and testosterone-
G were similar.
Figure 13 The single concentration transport assays of the androgen glucuronides. The concentration 
was 1 μM and the incubation time was 3 min.
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The transport kinetic characterization of MRP2 and MRP3 revealed that the Km values of 
MRP2 for androgen glucuronides were much higher than the respective values of MRP3 (Figure 
14 and Table 10). This resembles the case of estrogen glucuronides in which the similar 
differences between these two transporters were found (Figure 12 and Table 9). Interestingly, the 
MRP2 transport kinetics of androsterone-G and epitestosterone-G were fitted better to Hill’s 
equation than to the Michaelis-Menten equation (Table 10), although the resulting h-values were 
lower (1.4) than in the case of estradiol-17β-G (h = 2.3, Table 7). Furthermore, the apparent 
affinity of androgen glucuronides to MRP3 ranged from the Km value of 0.36 μM for 
etiocholanolone-G to the Km value of 51 μM for dehydroepiandrosterone-G. The kinetic constants 
of MRP2 transport of different androgen glucuronides were at similar range and these high Km
values suggest a low affinity transport of androgen glucuronides by MRP2 (Table 10).
Table 10. The derived kinetic constants for the transport kinetic data in Figure 14.
Substrate Km (95% CI), μM Vmax (95% CI), pmol/min/mg total protein 
MRP2 
Androsterone-G 
S50 = 160 (114-206)  
h = 1.41 (1.10-1.72) 344 (290-399) 
Dehydroepiandrosterone-G 155 (130-180) 816 (761-871) 
Epitestosterone-G 
S50 = 197 (107-287)  
h = 1.44 (0.98-1.90) 484 (353-614) 
Etiocholanolone-G 120 (57.7-183) 692 (555-828) 
Testosterone-G 428 (310-546) 1410 (1180-11640) 
MRP3 
Androsterone-G 3.65 (2.99-4.32) 295 (281-310) 
Dehydroepiandrosterone-G 51.0 (39.1-62.9) 88.4 (78-98.8) 
Epitestosterone-G 1.93 (1.33-2.52) 202 (189-216) 
Etiocholanolone-G 0.357 (0.188-0.527) 203 (193-212) 
Testosterone-G 13.7 (7.14-20.3) 136 (111-161) 
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Figure 14 The transport kinetics of the androgen glucuronides. The incubation time in the transport 
reactions was 1 min for MRP3, except 3 min in the case of dehydroepiandrosterone-G. 
Transport reaction incubation times for MRP2 were 2 and 6 min in the case of 
epitestosterone-G and androsterone-G, respectively, and 4 min in the case of the other 
glucuronides. The lines represent fitting of the data to the Michaelis-Menten equation, 
except for MRP2 and its transport of androsterone-G and epitestosterone-G that were fitted 
to Hill’s equation. Only error bars above data points are shown for clarity.
0 100 200 300 400 500
0
200
400
600
800
[Androgen glucuronide], μM
A
TP
-d
ep
en
de
nt
 t
ra
ns
po
rt
(p
m
ol
/m
in
/m
g 
to
ta
l p
ro
te
in
)
0 25 50 75 100
0
100
200
300
[Androgen glucuronide], μM
A
TP
-d
ep
en
de
nt
 t
ra
ns
po
rt
(p
m
ol
/m
in
/m
g 
to
ta
l p
ro
te
in
)
Testosterone-G Epitestosterone-G
Etiocholanolone-GAndrosterone-G
Dehydroepiandrosterone-G
MRP2
MRP3
43
6 DISCUSSION
6.1 Structural features in the substrates of MRP2, MRP3, MRP4 and 
BCRP
MRP3 transported every glucuronide that was investigated in this thesis, with the exception of 
nicotine-G and cotinine-G. It is difficult to explain why MRP3, or any other transporter, was 
unable to transport these two glucuronides. One possible reason can be the positively charged 
nitrogen atoms in nicotine-G and cotinine-G, which are otherwise rather similar structures to the 
other glucuronides investigated in this thesis (Table 6). MRPs transport mostly anionic 
compounds, and thus it is possible that these transporters repel structures with positive charges.85
Apart from these two compounds, MRP3 appears to be a highly versatile transporter for all types 
of glucuronides, even if the apparent affinities may greatly vary between different compounds. 
MRP3 transports several glucuronides at low Km values, ranging from 0.2 to 14 μM, including the 
glucuronides of ethinylestradiol, etoposide, hyocholate, hyodeoxycholate, resveratrol and several 
phytoestrogens, including enterodiol and genistein.177,191,198-200 On the other hand, the uptake of 
morphine-3-glucuronide into MRP3 vesicles is high but occurs at a low affinity with a Km value
over 500 μM.173,174 Both the aforementioned reports are in line with the results in this thesis, 
which indicate that MRP3 is a high affinity glucuronide transporter, particularly in the case of 
steroid glucuronides, but in some cases it might exhibit high Km values toward its substrates. The
presence of a basic nitrogen in the structure is a common feature shared by the low affinity
substrates of MRP3, among which are morphine-3-glucuronide (logD7.4 = -3.49, PSA = 149 Å2),
trans-3’-hydroxycotinine-G, R- and S-propranolol-G. As discussed above, this feature might 
hamper the transport of MRP3.
MRP2 appears to be a more selective transporter, with lower affinities toward the glucuronides 
investigated in this thesis. Some smaller glucuronides are not transported by MRP2 (I and II), 
whereas the steroid glucuronides are substrates of MRP2 with high Vmax but also high Km values 
(III and IV). These results indicate that the binding site of MRP2 might be larger and more flexible 
in comparison to MRP3. This is further supported by the findings that MRP2, but not MRP3, 
transports glutathione conjugates that are rather large due to the high MW of the glutathione 
moiety, 307 Da.125,201 Furthermore, Kato and coworkers analyzed the uptake of 10 different β-
lactam antibiotics into human MRP2 vesicles and found that only compounds with a MW over 
500 Da were transported efficiently.202 In addition, MRP2 does not transport the glucuronide 
conjugates of 7-hydroxycoumarin, edaravone and gaboxadol, all of which have a MW below 350 
Da.141,143,145 Together, MRP2 and MRP3 transport a wide range of glucuronides, but MRP2 
appears to be restricted to higher MW glucuronides and have high Km values, whereas MRP3 
mostly exhibits a high affinity transport of the same compounds (Table 6 and the Results section).
The findings on MRP4 within this thesis are interesting, because this transporter was active in 
the transport of only five of the compounds investigated. The intrinsic molecular properties of 
these compounds (1-hydroxypyrene-G, 1-naphthol-G, 4-methylumbelliferone-G, estradiol-17β-G
and estriol-16α-G) are different and the reasons for the substrate selectivity of MRP4 are difficult 
to explain. In particular, because the Km values differed from low to moderate, 3 to 170 μM. MRP4 
efficiently transports glucuronides of edaravone and 7-hydroxycoumarin, with the Km values of 
10 and 60 μM, respectively.143,145 These values are in a similar range with the MRP4 substrates 
identified in this thesis (Table 7-9). In addition, MRP4 transports estradiol-17β-G and gemfibrozil 
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glucuronide similarly to MRP2 and MRP3, but it does not transport the glucuronides of E3040,
morphine or troglitazone even though these compounds are substrates for MRP2 and MRP3.158,174
Furthermore, MRP4 is able to transport a variety of different compounds such as cAMP, cGMP, 
dehydroepiandrosterone sulfate, as well as prostaglandin E1 and E2.195,203,204 Thus, MRP4 is a 
more selective transporter than MRP2 and MRP3, and among the substrates and non-substrates
identified in this thesis it is difficult to define the reasons for MRP4’s selectivity (Table 6).
Multiple flavonoid glucuronides may be transported by the human BCRP according to data 
from in vivo Bcrp-knockout mice studies (Table 5). In vitro studies with human BCRP membrane 
vesicles have confirmed the high transport of several glucuronide conjugates of flavonoids,
including the glucuronides of baicalein, scutellarein, resveratrol and different 
dihydroxyflavonones.142,177,205,206 These flavonoid glucuronides share a rather flat structure that 
contains two or three aromatic rings. Furthermore, BCRP efficiently transports the glucuronide 
conjugate of SN-38, an active metabolite of the anticancer drug irinotecan, with a Km value of 
approximately 20 μM.207 The structure of SN-38 is completely planar, with the exception of two 
ethyl side chains, and it contains aromatic rings. The results from this thesis further support the 
role of BCRP in the disposition of glucuronide conjugates, although the BCRP-mediated transport 
appears to be rather selective for flat and aromatic structures. A recently solved high-resolution 
cryo-electron microscopy structure of BCRP revealed a slit substrate-binding pocket, which is 
able to accommodate flat, hydrophobic and polycyclic substrates.208
BCRP has been postulated to be more important in the transport of sulfate conjugates than 
glucuronides.209-211 Although animal Bcrp-knockout studies have revealed that BCRP is capable 
of transporting glucuronide conjugates as well (Table 5), data with human transporters are still 
scarce.125 This thesis deepens the understanding of the significance of BCRP in the transport of 
glucuronide conjugates. First, BCRP appears to be more selective by transporting fewer 
glucuronides than MRP2 and MRP3, as discussed above. However, in some cases BCRP should 
be considered as the transporter that affects biliary and intestinal excretion of glucuronide 
metabolites. Second, BCRP might be a low affinity but high capacity transporter for glucuronides 
in comparison to sulfate conjugates. For example, the Km value for estrone-3-G (74 μM) is over a 
magnitude higher than for estrone sulfate (1 μM) but the Vmax for estrone sulfate is 10-fold lower
(III), which results in only 5-fold higher intrinsic clearance for the sulfate conjugate by BCRP 
(III). Similarly, BCRP transports resveratrol sulfate at a higher apparent affinity than the 
corresponding glucuronide, the Km values of 5 versus 120 μM.177 In addition, 4-
methylumbelliferone-G is a weak substrate for BCRP (I), while the sulfate conjugate of the same 
compound is highly transported by BCRP.210
None of the glucuronides tested had higher uptake into P-gp vesicles in comparison to the 
control vesicles. The data in this thesis further verify that P-gp is not involved in the transport of 
glucuronide metabolites of drugs.125 Furthermore, the P-gp transport results in this thesis 
emphasize the importance of proper control preparations within in vitro assays, because some of 
the compounds studied were transported into P-gp vesicles but similar transport occurred into the 
corresponding control vesicles (CTRL+C). For example, estradiol-17β-G is a rare exception among 
glucuronides reported as substrates for P-gp in the vesicular transport assay.212 However, Huang 
and coworkers employed non-infected control cells for the control vesicle preparations, which 
likely exhibited a lower expression of endogenous transporters and subsequently a lower transport 
activity.212 In this thesis, the control vesicles were prepared either from the empty-virus infected 
cells (I and III) or from cells that were infected with a virus encoding a transport-deficient protein
of a human transporter (II and IV). As a result, the control preparations used in this thesis have 
similar endogenous transport activity as cells infected with the virus encoding a functional human 
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recombinant transporter. Furthermore, cholesterol addition to the membrane vesicle preparations 
is crucial for the proper transport activity of BCRP and P-gp, but this addition also activates 
endogenous transporters.192,193,213 Due to this high activity in the control preparations,
determination of transport kinetics for the BCRP-mediated transport of 4-methylumbelliferone-G
and 1-naphthol-G was not feasible.
6.2 Impact of the efflux transporters on glucuronide metabolite 
disposition
Important issues that remain to be solved are the tissue-specific function of BCRP and in which 
tissues this transporter affects the elimination of drug metabolites. Undeniably, BCRP is markedly 
important in restricting the entry of drugs to the brain over the BBB, together with P-gp.7,70 In 
addition, a few but significant BCRP-mediated drug-drug interactions are due to the inhibition of 
intestinal BCRP, which supports a role for BCRP in the absorption of drugs.214 Nevertheless, the 
expression of this transporter in the human liver is 10-fold lower than the expression of MRP2, 
and some studies even suggest that BCRP is almost absent from the human liver.77,83 Similarly, 
the protein expression of BCRP in the human kidney is low or has not been detected.86-88
Unfortunately, no comprehensive data are available for the hepatic expression of Bcrp in mice, 
but it is suggested to be low, as in humans, whereas the expression of this transporter in the mouse 
kidney is much higher in comparison to the human tissue.86,215
Based on the results from animal experiments, Bcrp affects the systemic exposure and biliary 
excretion of several glucuronide and sulfate metabolites after either oral or parenteral 
administration of the parent compound (Table 5). For example, the cumulative biliary excretion 
of 4-methylumbelliferone-G was reduced to half in liver perfusions from both Mrp2- and Bcrp-
knockout mice. On the other hand, only the knockout of Bcrp, but not Mrp2, affected the biliary 
excretion of 4-methylumbelliferone sulfate by abolishing its excretion almost completely.148
Furthermore, the CLr of 4-methylumbelliferone sulfate was unchanged in Bcrp-knockout mice 
after intravenous infusion of it, although the same strain of mice exhibited decreased CLr of E3040 
sulfate by two-fold in comparison to wild type animals.216 Both 4-methylumbelliferone and E3040
sulfate are actively secreted in urine in mice and are highly transported by the human BCRP.210,216
These contradictory findings could be partly explained by the different fe values of Bcrp in 
different tissues and for different compounds. First, in the mouse livers, the fe for the Bcrp-
mediated biliary excretion of 4-methylumbelliferone sulfate is 1.180 Second, the respective fe
values for Mrp2 and BCRP in the case of 4-methylumbelliferone-G are 0.33 and 0.73, 
respectively. Therefore, the sole contribution of Bcrp to the biliary excretion of 4-
methylumbelliferone sulfate explains the complete abolishment of its biliary excretion in the
Bcrp-knockout mice. On the other hand, the mild effect of Bcrp-knockout on the biliary excretion
of 4-methylumbelliferone-G is explained by similar contribution of both Mrp2 and Bcrp to this 
excretion pathway (Section 2.3.2 and Equation 5). Lastly, Mrp4 contributes to the basolateral 
hepatic excretion of 4-methylumbelliferone sulfate.149 The activity of Mrp4 may compensate for 
the impaired renal excretion of 4-methylumbelliferone sulfate also in the kidneys of the Bcrp-
knockout mice and, therefore, explain the unchanged CLr of this compound in the knockout mice 
in comparison to wild type mice. Thus, not only the absolute protein expression of a transporter
in a tissue affects its contribution to the excretion of its substrates, but also the relative contribution 
of the transporter in each tissue is an important parameter.
46
Estrone-3-G and estradiol-3-G were identified as the best substrates for BCRP within this 
thesis, but none of the androgen glucuronides were transported by this transporter. Apart from 
dehydroepiandrosterone-G, all the estrogen and androgen glucuronides were transported by 
MRP3 at high apparent affinities. Furthermore, MRP2 contributed to the transport of the same 
steroid glucuronides, even if at high Km values. Estrone and estradiol are excreted about 50% to 
bile in humans after parenteral administration, whereas the biliary excretion of estriol is around 
20%.217,218 Moreover, the biliary excretion of testosterone is about 10% in humans, whereas for 
androsterone and etiocholanolone it is negligible.219,220 Since these steroids are excreted as 
conjugates, BCRP may play a key role in the high biliary excretion of estrogens, but not 
androgens.
MRP2 and MRP3 did not appear to distinguish between androgen and estrogen glucuronides 
but transported both type of compounds. Thus, it is evident that these conjugates are excreted via 
both bile and urine. However, the relative contribution of these two pathways is difficult to 
estimate. It is interesting to speculate whether the lower affinity of testosterone-G to MRP3 in 
comparison to androsterone-G and etiocholanolone-G increases the relative contribution of MRP2 
to the biliary excretion of testosterone-G. On the other hand, the contribution of hepatic uptake 
transporters, particularly OATPs, to the disposition of androgen glucuronides cannot be excluded. 
Estradiol-17β-G is a well-established substrate for the human hepatic uptake transporters 
OATP1B1 and OATP1B3, which can reduce the urinary excretion of this glucuronide by the so-
called hepatocyte hopping.68,221 This phenomenon enhances the transport of the glucuronide back 
into hepatocytes from the basolateral side and its subsequent availability for the biliary excretion, 
even in the presence of high basolateral efflux. Unfortunately, no in vitro data on human hepatic 
uptake of androgen glucuronides or other estrogen glucuronides are currently available. However, 
data are available on human in vivo excretion of several androgen and estrogen glucuronides 
following their parenteral administration. In humans, about 50% and 7% of parenterally 
administered estradiol-17β-G and estrone-3-G are excreted in bile, whereas about 20% of estriol-
16α-G is excreted via bile.222,223 In contrast, estriol-3-G or androsterone-G are not excreted in bile 
but are rapidly cleared in urine after their parenteral administration.224,225 Furthermore, estradiol-
3-G and testosterone-G partly undergo metabolism after their parenteral administration suggesting
active transport into hepatocytes and excretion in bile, although this pathway accounts for less 
than 50% of the dose based on the formed metabolites.226,227 Thus, it is clear that even in the 
presence of high basolateral efflux of a metabolite from the liver, the sum of influx and efflux 
over the basolateral membrane, namely the net flux, determines the disposition of a metabolite 
and be the driving force for biliary excretion.
The glucuronides of 4-methylumbelliferone, R- and S-propranolol and trans-3’-
hydroxycotinine were not substrates for MRP2 or BCRP but were transported by MRP3, or both 
MRP3 and MRP4 in the case of 4-methylumbelliferone-G. In humans, the clearance of 4-
methylumbelliferone via glucuronidation is high, and the rapid urinary excretion of 4-
methylumbelliferone-G accounts for 93% of the total dose.228 Propranolol glucuronides and trans-
3’-hydroxycotinine-G are also completely excreted in urine.229-232 Furthermore, 4-
methylumbelliferone-G is neither a substrate for OATP1B1 nor actively transported into rat 
hepatocytes.121,158 Similar data are not available for propranolol glucuronides, but these 
metabolites are accumulated almost 20-fold in blood of patients with renal failure, which suggests 
no major hepatic uptake for propranolol glucuronides, but rather excessive renal excretion.233
Hence, MRP3 is probably, and almost solely, responsible for the hepatic excretion of 4-
methylumbelliferone-G, trans-3’-hydroxycotinine-G, as well as R- and S-propranolol-G. On the 
other hand, the contribution of hepatic MRP4 to the transport of 4-methylumbelliferone-G is 
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difficult to estimate, because the expression level of this transporter in the human liver is generally 
low compared to that of MRP3.83
In the kidney, MRP4 appears to be an important efflux transporter for the active secretion of 
glucuronides, which is suggested by the high CLr of 4-methylumbelliferone-G and estriol-16α-G,
exceeding the GFR by at least three-fold.228,234 On the other hand, the CLr of androsterone-G,
etiocholanolone-G, estriol-3-G and propranolol glucuronides are similar to the GFR, and no active 
secretion for trans-3’-hydroxycotinine-G has been reported.230,234-236 Thus, MRP4 likely 
contributes to the active renal secretion of 4-methylumbelliferone-G and estriol-16α-G but not to
that of propranolol glucuronides, estriol-3-G or trans-3’-hydroxycotinine-G. These findings agree 
well with the in vitro results of this thesis, according to which only the former two compounds 
are substrates for MRP4. It should be noted that the glucuronidation of 4-methylumbelliferone
and estriol in the kidney could not be excluded, because the UGTs that catalyze their 
glucuronidation are expressed also in this tissue.31,237,238
6.3 Future prospects
MRP2 and MRP3 appear to be rather unselective in the transport of different glucuronides, and 
particularly MRP3 transported all the glucuronides investigated, except nicotine-G and cotinine-
G. The transport of these two glucuronides was also tested in MRP1, MRP5 and MRP6 membrane 
vesicles, but without success (II). Interestingly, similar examples have been recently reported 
where no currently known transporter could be identified for the active uptake or efflux of a 
drug.239,240 For example, atovaquone is an anionic drug that is exceptionally highly concentrated 
in human bile.95 Patel and coworkers found in vitro biliary excretion of atovaquone in human 
hepatocytes, however, they could not identify neither the uptake nor the efflux transporter among 
the known drug transporters for this drug.240 Thus, it is possible that several other transporters that
affect drug and drug metabolite disposition are still to be discovered.
The empirical MW threshold value for biliary excretion of anionic compounds is about 400-
500 Da.28,100,101 In addition, the ECCS predicts that acids with MW above 400 Da are primarily 
cleared from the systemic circulation by hepatic OATPs.6 Even if these values can only be used 
as good estimators for the main excretion route of a drug or drug metabolite, some correlation 
appears to be found within the glucuronides investigated in this thesis and their biliary excretion. 
For example, the glucuronides below 400 Da were not substrates for MRP2 and many of them are 
excreted exclusively in urine. On the other hand, literature reports suggest that some of the 
glucuronides above 400 Da included in this thesis may be substrates for the hepatic uptake 
transporters but with rather different efficiencies, as discussed above. Hence, it would be essential 
and interesting, in the future, to understand better the substrate specificities of hepatic OATPs and 
their effects on the net flux over the hepatic basolateral membrane. Specific questions would be 
whether the substrate preferences of OATPs and MRP2 significantly overlap and whether the 
OATP-MRP2 interplay determines the empirical MW threshold value of 400-500 Da for anionic 
compounds, such as glucuronides.
In addition to OATPs, OAT2 and OAT7 in the liver as well as OAT1 and OAT3 in the kidney 
may affect the disposition of glucuronide metabolites.7,73,74 So far, no well-characterized 
glucuronide conjugate substrates have been reported for OAT2 or OAT7.74,105,123,241,242 On the
other hand, several glucuronides have been reported as substrates for OAT3, and a few for 
OAT1.105,123,183,184,242-244 Thus, it would be interesting to study the OAT1/3-MRP4 interplay in the 
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kidney in more detail and whether 4-methylumbelliferone-G or estriol-16-G are substrates also 
for the renal OATs. In addition, MRP2 is expressed in the same membrane with MRP4 in the 
kidney and it transports androsterone-G, etiocholanolone-G and estriol-3-G, but the CLr of these 
metabolites is similar to the GFR.234,235 Hence, it could be suggested that they are not substrates 
for OAT1 or OAT3, and that the overlapping substrate preference exists only between OAT1/3 
and MRP4.
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7 Conclusions
Efflux transport of several glucuronide metabolites of drugs and drug-like compounds, such as 
androgens and estrogens, were investigated in this thesis, employing the vesicular transport assay. 
The human efflux transporters MRP2, MRP3, MRP4, BCRP and P-gp were included in the 
studies. Based on the results, MRP2 and MRP3 are rather versatile transporters that transport 
almost all the compounds investigated, whereas MRP4 and BCRP appeared to be more selective 
and transport only some of the compounds. Transport kinetic analyses revealed mostly low Km
values for MRP3 and the lowest value was even below 1 μM. On the other hand, MRP2 had 
clearly lower apparent affinities, Km values over 100 μM, or even no transport of some substrates 
that MRP3 transported. MRP4 transported only one of the nine steroid glucuronides investigated, 
but had high activity toward glucuronides containing small planar rings. BCRP was highly active 
only toward estrogen glucuronides and 1-hydroxypyrene glucuronide, which indicates that 
aromatic rings are important for binding to this transporter. P-gp did not transport any of the 
glucuronides investigated, and therefore it appears that this transporter does not contribute to the
disposition of glucuronide metabolites of drugs in humans.
Together, MRP2 and MRP3 are important efflux transporters in the human liver and intestine, 
where they affect the disposition of a high variety of different glucuronide metabolites of drugs. 
BCRP and MRP4 may be important in specific cases, MRP4 particularly in the kidney where it 
contributes to the active secretion of some glucuronide metabolites.
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